Patent Application
20230340159
The contents of the electronic sequence listing (T083370042US01-SEQ-ZJG.xml; size: 805,875 bytes; and date of creation: May 4, 2023) is herein incorporated by reference in its entirety.
The selective destruction of an individual cell or a specific cell type is often desirable in a variety of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy tumor cells, while leaving healthy cells and tissues as intact and undamaged as possible. One such method is by inducing an immune response against the tumor, to make immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) attack and destroy tumor cells.
The use of intact monoclonal antibodies (mAb), which provide superior binding specificity and affinity for a tumor-associated antigen, have been successfully applied in the area of cancer treatment and diagnosis. However, the large size of intact mAbs, their poor biodistribution, low potency and long persistence in the blood pool have limited their clinical applications. For example, intact antibodies can exhibit specific accumulation within the tumor area. In biodistribution studies, an inhomogeneous antibody distribution with primary accumulation in the peripheral regions is noted when precisely investigating the tumor. Due to tumor necrosis, inhomogeneous antigen distribution and increased interstitial tissue pressure, it is not possible to reach central portions of the tumor with intact antibody constructs. In contrast, smaller antibody fragments show rapid tumor localization, penetrate deeper into the tumor, and also, are removed relatively rapidly from the bloodstream. However, many antibodies, including scFvs and other constructs, show “on target/off tumor” effects, wherein the molecule is active on non-tumor cells, causing side effects, some of which can be toxic. The present invention is related to novel constructs that are selectively activated in the presence of tumor proteases.
In one aspect, provided is a fusion protein comprising, from N- to C-terminal: (a) a first sdABD that binds HER2 (sdABD-HER2); (b) a first domain linker; (c) a constrained Fv domain comprising: (i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; (ii) a constrained non-cleavable linker (CNCL); and (iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; (d) a second domain linker; (e) a second sdABD-HER2; (f) a cleavable linker (CL); (g) a constrained pseudo Fv domain comprising: (i) a first pseudo variable light domain; (ii) a non-cleavable linker (NCL); and (iii) a first pseudo variable heavy domain; (h) a third domain linker; and (i) a third sdABD that binds to human serum albumin (sdABD-HSA); wherein the first variable heavy domain and the first variable light domain of the constrained Fv domain are capable of binding human CD3 but the constrained pseudo Fv domain does not bind CD3; the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and the first variable light domain and the first pseudo variable heavy domain intramolecularly associate to form an inactive Fv.
In some embodiments, the first and/or second sdABD-HER2 has an amino acid sequence comprising a set of CDRs selected from the group consisting of: (a) a sdCDR1 of SEQ ID NO:194 a sdCDR2 of SEQ ID NO:195 and a sdCDR3 of SEQ ID NO:196; (b) a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219 and a sdCDR3 of SEQ ID NO:220; (c) a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227 and a sdCDR3 of SEQ ID NO:228; (d) a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239 and a sdCDR3 of SEQ ID NO:240; (e) a sdCDR1 of SEQ ID NO:142, a sdCDR2 of SEQ ID NO:143 and a sdCDR3 of SEQ ID NO:144; (f) a sdCDR1 of SEQ ID NO146, a sdCDR2 of SEQ ID NO:147 and a sdCDR3 of SEQ ID NO:148; (g) a sdCDR1 of SEQ ID NO:150, a sdCDR2 of SEQ ID NO:151 and a sdCDR3 of SEQ ID NO:152; (h) a sdCDR1 of SEQ ID NO:154, a sdCDR2 of SEQ ID NO:155, and a sdCDR3 of SEQ ID NO:156; (i) a sdCDR1 of SEQ ID NO:158, a sdCDR2 of SEQ ID NO:159, and a sdCDR3 of SEQ ID NO:160; (j) a sdCDR1 of SEQ ID NO:162, a sdCDR2 of SEQ ID NO:163, and a sdCDR3 of SEQ ID NO:164; (k) a sdCDR1 of SEQ ID NO:166, a sdCDR2 of SEQ ID NO:167, and a sdCDR3 of SEQ ID NO:168; (1) a sdCDR1 of SEQ ID NO:170, a sdCDR2 of SEQ ID NO:171, and a sdCDR3 of SEQ ID NO:172; (m) a sdCDR1 of SEQ ID NO:174, a sdCDR2 of SEQ ID NO:175, and a sdCDR3 of SEQ ID NO:176; (n) a sdCDR1 of SEQ ID NO:178, a sdCDR2 of SEQ ID NO:179, and a sdCDR3 of SEQ ID NO:180; (o) a sdCDR1 of SEQ ID NO:182, a sdCDR2 of SEQ ID NO:183, and a sdCDR3 of SEQ ID NO:184; (p) a sdCDR1 of SEQ ID NO:186, a sdCDR2 of SEQ ID NO:187, and a sdCDR3 of SEQ ID NO:188; (q) a sdCDR1 of SEQ ID NO:190, a sdCDR2 of SEQ ID NO:191, and a sdCDR3 of SEQ ID NO:192;(r) a sdCDR1 of SEQ ID NO:194, a sdCDR2 of SEQ ID NO:195, and a sdCDR3 of SEQ ID NO:196; (s) a sdCDR1 of SEQ ID NO:198, a sdCDR2 of SEQ ID NO:199, and a sdCDR3 of SEQ ID NO:200; (t) a sdCDR1 of SEQ ID NO:202, a sdCDR2 of SEQ ID NO:203, and a sdCDR3 of SEQ ID NO:204; (u) a sdCDR1 of SEQ ID NO:206, a sdCDR2 of SEQ ID NO:207, and a sdCDR3 of SEQ ID NO:203; (v) a sdCDR1 of SEQ ID NO:210, a sdCDR2 of SEQ ID NO:211, and a sdCDR3 of SEQ ID NO:212; (w) a sdCDR1 of SEQ ID NO:214, a sdCDR2 of SEQ ID NO:215, and a sdCDR3 of SEQ ID NO:216; (x) a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219, and a sdCDR3 of SEQ ID NO:220; (y) a sdCDR1 of SEQ ID NO:222, a sdCDR2 of SEQ ID NO:223, and a sdCDR3 of SEQ ID NO:224; (z) a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227, and a sdCDR3 of SEQ ID NO:228; (aa) a sdCDR1 of SEQ ID NO:230, a sdCDR2 of SEQ ID NO:231, and a sdCDR3 of SEQ ID NO:232; (ab) a sdCDR1 of SEQ ID NO:234, a sdCDR2 of SEQ ID NO:235, and a sdCDR3 of SEQ ID NO:236; (ac) a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239, and a sdCDR3 of SEQ ID NO:240; (ad) a sdCDR1 of SEQ ID NO:242, a sdCDR2 of SEQ ID NO:243, and a sdCDR3 with SEQ ID NO:244; and (ae) a sdCDR1 of SEQ ID NO:500, a sdCDR2 of SEQ ID NO:501, and a sdCDR3 with SEQ ID NO:502; (af) a sdCDR1 of SEQ ID NO:504, a sdCDR2 of SEQ ID NO:505, and a sdCDR3 with SEQ ID NO:506; (ag) a sdCDR1 of SEQ ID NO:508, a sdCDR2 of SEQ ID NO:509, and a sdCDR3 with SEQ ID NO:510; and (ah) a sdCDR1 of SEQ ID NO:512, a sdCDR2 of SEQ ID NO:513, and a sdCDR3 with SEQ ID NO:5.
In some embodiments, the first and/or second sdABD-HER2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:193, SEQ ID NO:217, SEQ ID NO:225, SEQ ID NO:237, SEQ ID NO:141, SEQ ID NO:145, SEQ ID NO:149, SEQ ID NO:153, SEQ ID NO:157, SEQ ID NO:161, SEQ ID NO:165, SEQ ID NO:169, SEQ ID NO:173, SEQ ID NO:177, SEQ ID NO:181, SEQ ID NO:185, SEQ ID NO:189,, SEQ ID NO:197, SEQ ID NO:201, SEQ ID NO:205, SEQ ID NO:209, SEQ ID NO:213, SEQ ID NO:221, SEQ ID NO:229, SEQ ID NO:233, SEQ ID NO:241, SEQ ID NO:499, SEQ ID NO:503, SEQ ID NO:507, and SEQ ID NO:511.
In some embodiments, the first sdABD-HER2 and the second sdABD-HER2 are the same.
In some embodiments, the first sdABD-HER2 and the second sdABD-HER2 are different.
In some embodiments, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo variable light domain is N-terminal to the pseudo variable heavy domain.
In some embodiments, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In some embodiments, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo variable light domain is N-terminal to the pseudo variable heavy domain.
In some embodiments, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In some embodiments, the third sdABD that binds to HSA (sdABD-HSA) has an amino acid sequence comprising: (a) a set of CDRs selected from the group consisting of (i) a sdCDR1 of SEQ ID NO:246, a sdCDR2 of SEQ ID NO:247, and a sdCDR3 of SEQ ID NO:248, and (ii) a sdCDR1 of SEQ ID NO:250, a sdCDR2 of SEQ ID NO:251, and a sdCDR3 of SEQ ID NO:252; or (b) an amino acid sequence selected from the group consisting of SEQ ID NO:245 and SEQ ID NO:249.
In some embodiments, the cleavable linker comprises a cleavage domain sequence selected from the group consisting of SEQ ID NOS:339-408 and 532-535.
In some embodiments, the cleavable linker is cleaved by a human protease selected from the group consisting of MMP2, MMP9, meprin A, meprin B, cathepsin S, capthepsin K, capthesin L, granzyme B, uPA, kallekriein7, matriptase, and thrombin.
In some embodiments, the fusion protein has an amino acid sequence selected from group consisting of SEQ ID NOS:459-484 and 491-494.
Provided herein is a nucleic acid encoding any of the fusion proteins described.
Provided herein is an expression vector comprising any of the nucleic acids described.
Provided herein is a host cell comprising any of the expression vectors described
In some aspects, provided is a method of making a fusion protein of the present disclosure comprising: (i) culturing the host cell described under conditions wherein the fusion protein is expressed and (ii) recovering the fusion protein.
In some aspects, provided is a method of treating cancer in a subject comprising administering any of the fusion proteins described to the subject.
In some aspects, provided is a single domain antigen binding domain (sdABD) that binds human HER2 (sdABD-HER2) comprising (i) an amino acid sequence selected from the group consisting of SEQ ID NO:141, SEQ ID NO:145, SEQ ID NO:149, SEQ ID NO:153, SEQ ID NO:157, SEQ ID NO:161, SEQ ID NO:165, SEQ ID NO:169, SEQ ID NO:173, SEQ ID NO:177, SEQ ID NO:181, SEQ ID NO:185, SEQ ID NO:189, SEQ ID NO:193, SEQ ID NO:197, SEQ ID NO:201, SEQ ID NO:205, SEQ ID NO:209, SEQ ID NO:213, SEQ ID NO:217, SEQ ID NO:221, SEQ ID NO:225, SEQ ID NO:229, SEQ ID NO:233, SEQ ID NO:237, SEQ ID NO:241, SEQ ID NO:499, SEQ ID NO:503, SEQ ID NO:507, and SEQ ID NO:511; or (ii) an amino acid sequence comprising a set of CDRs selected from the group consisting of: (a) a sdCDR1 of SEQ ID NO:194 a sdCDR2 of SEQ ID NO:195 and a sdCDR3 of SEQ ID NO:196; (b) a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219 and a sdCDR3 of SEQ ID NO:220; (c) a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227 and a sdCDR3 of SEQ ID NO:228; (d) a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239 and a sdCDR3 of SEQ ID NO:240; (e) a sdCDR1 of SEQ ID NO:142, a sdCDR2 of SEQ ID NO:143 and a sdCDR3 of SEQ ID NO:144; (f) a sdCDR1 of SEQ ID NO146, a sdCDR2 of SEQ ID NO:147 and a sdCDR3 of SEQ ID NO:148; (g) a sdCDR1 of SEQ ID NO:150, a sdCDR2 of SEQ ID NO:151 and a sdCDR3 of SEQ ID NO:152; (h) a sdCDR1 of SEQ ID NO:154, a sdCDR2 of SEQ ID NO:155, and a sdCDR3 of SEQ ID NO:156; (i) a sdCDR1 of SEQ ID NO:158, a sdCDR2 of SEQ ID NO:159, and a sdCDR3 of SEQ ID NO:160; (j) a sdCDR1 of SEQ ID NO:162, a sdCDR2 of SEQ ID NO:163, and a sdCDR3 of SEQ ID NO:164; k) a sdCDR1 of SEQ ID NO:166, a sdCDR2 of SEQ ID NO:167, and a sdCDR3 of SEQ ID NO:168; (1) a sdCDR1 of SEQ ID NO:170, a sdCDR2 of SEQ ID NO:171, and a sdCDR3 of SEQ ID NO:172; (m) a sdCDR1 of SEQ ID NO:174, a sdCDR2 of SEQ ID NO:175, and a sdCDR3 of SEQ ID NO:176; (n) a sdCDR1 of SEQ ID NO:178, a sdCDR2 of SEQ ID NO:179, and a sdCDR3 of SEQ ID NO:180; (o) a sdCDR1 of SEQ ID NO:182, a sdCDR2 of SEQ ID NO:183, and a sdCDR3 of SEQ ID NO:184; (p) a sdCDR1 of SEQ ID NO:186, a sdCDR2 of SEQ ID NO:187, and a sdCDR3 of SEQ ID NO:188; (q) a sdCDR1 of SEQ ID NO:190, a sdCDR2 of SEQ ID NO:191, and a sdCDR3 of SEQ ID NO:192; (r) a sdCDR1 of SEQ ID NO:194, a sdCDR2 of SEQ ID NO:195, and a sdCDR3 of SEQ ID NO:196; (s) a sdCDR1 of SEQ ID NO:198, a sdCDR2 of SEQ ID NO:199, and a sdCDR3 of SEQ ID NO:200; (t) a sdCDR1 of SEQ ID NO:202, a sdCDR2 of SEQ ID NO:203, and a sdCDR3 of SEQ ID NO:204; (u) a sdCDR1 of SEQ ID NO:206, a sdCDR2 of SEQ ID NO:207, and a sdCDR3 of SEQ ID NO:203; (v) a sdCDR1 of SEQ ID NO:210, a sdCDR2 of SEQ ID NO:211, and a sdCDR3 of SEQ ID NO:212; (w) a sdCDR1 of SEQ ID NO:214, a sdCDR2 of SEQ ID NO:215, and a sdCDR3 of SEQ ID NO:216; (x) a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219, and a sdCDR3 of SEQ ID NO:220; (y) a sdCDR1 of SEQ ID NO:222, a sdCDR2 of SEQ ID NO:223, and a sdCDR3 of SEQ ID NO:224; (z) a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227, and a sdCDR3 of SEQ ID NO:228; aa) a sdCDR1 of SEQ ID NO:230, a sdCDR2 of SEQ ID NO:231, and a sdCDR3 of SEQ ID NO:232; ab) a sdCDR1 of SEQ ID NO:234, a sdCDR2 of SEQ ID NO:235, and a sdCDR3 of SEQ ID NO:236; ac) a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239, and a sdCDR3 of SEQ ID NO:240; ad) a sdCDR1 of SEQ ID NO:242, a sdCDR2 of SEQ ID NO:243, and a sdCDR3 with SEQ ID NO:244; ae) a sdCDR1 of SEQ ID NO:500, a sdCDR2 of SEQ ID NO:501, and a sdCDR3 with SEQ ID NO:502; af) a sdCDR1 of SEQ ID NO:504, a sdCDR2 of SEQ ID NO:505, and a sdCDR3 with SEQ ID NO:506; ag) a sdCDR1 of SEQ ID NO:508, a sdCDR2 of SEQ ID NO:509, and a sdCDR3 with SEQ ID NO:510; and ah) a sdCDR1 of SEQ ID NO:512, a sdCDR2 of SEQ ID NO:513, and a sdCDR3 with SEQ ID NO:514.
In some aspects, provided is a fusion protein comprising, from N- to C-terminal: (a) a first sdABD that binds a tumor target antigen (sdABD-TTA); (b) a first domain linker; (c) a constrained Fv domain comprising: (i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; (ii) a constrained non-cleavable linker (CNCL); and (iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; d) a second domain linker; e) a second sdABD-TTA; f) a cleavable linker (CL); (g) a constrained pseudo Fv domain comprising: (i) a first pseudo variable light domain; (ii) a non-cleavable linker (NCL); and (iii) a first pseudo variable heavy domain; (h) a third domain linker; and (i) a third sdABD that binds to human serum albumin (sdABD-HSA); wherein the first variable heavy domain and the first variable light domain of the constrained Fv domain are capable of binding human CD3 but the constrained pseudo Fv domain does not bind CD3; the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; the first variable light domain and the first pseudo variable heavy domain intramolecularly associate to form an inactive Fv and wherein either (1) the first sdABD-TTA is a sdABD-HER2 or a sdABD-LyPD3, and the second sdABD-TTA is selected from the group consisting of a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-HER2, a sdABD-LyPD3 and a sdABD-Trop2; or (2) the first sdABD-TTA is selected from the group consisting of a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-HER2, a sdABD-LyPD3 and a sdABD-Trop2, and the second sdABD-TTA is a sdABD-HER2 or a sdABD-LyPD3.
In some embodiments, the first and second sdABD-TTA are each a sdABD-LyPD3. In some embodiments, the first and second sdABD-LPYD3 are the same. In some embodiments, the first and second sdABD-LPYD3 are different.
In some embodiments of the fusion protein, (a) the first sdABD-TTA is a sdABD-HER2 and the second sdABD-TTA is selected from the group consisting of a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-LyPD3, and a sdABD-Trop2; (b) the first sdABD-TTA is a sdABD-LyPD3 and the second sdABD-TTA is selected from the group consisting a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-HER2, and a sdABD-Trop2; (c) the first sdABD-TTA is selected from the group consisting a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-LyPD3, and a sdABD-Trop2 and the second TTA is a sdABD-HER2; or (d) the first sdABD-TTA is selected from the group consisting a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-FOLR1, a sdABD-LyPD3, and a sdABD-Trop2 and the second TTA is a sdABD-LyPD3.
In some embodiments, the sdABD-HER2 comprises an amino acid sequence selected from the group consisting of: (a) a set of CDRs comprising a sdCDR1 of SEQ ID NO:194 a sdCDR2 of SEQ ID NO:195 and a sdCDR3 of SEQ ID NO:196; (b) a set of CDRs comprising a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219 and a sdCDR3 of SEQ ID NO:220; (c) a set of CDRs comprising a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227 and a sdCDR3 of SEQ ID NO:228; (d) a set of CDRs comprising a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239 and a sdCDR3 of SEQ ID NO:240; (e) a set of CDRs comprising a sdCDR1 of SEQ ID NO:142, a sdCDR2 of SEQ ID NO:143 and a sdCDR3 of SEQ ID NO:144; (f) a set of CDRs comprising a sdCDR1 of SEQ ID NO:146, a sdCDR2 of SEQ ID NO:147 and a sdCDR3 of SEQ ID NO:148; (g) a set of CDRs comprising a sdCDR1 of SEQ ID NO:150, a sdCDR2 of SEQ ID NO:151 and a sdCDR3 of SEQ ID NO:152; (h) a set of CDRs comprising a sdCDR1 of SEQ ID NO:154, a sdCDR2 of SEQ ID NO:155, and a sdCDR3 of SEQ ID NO:156; (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:158, a sdCDR2 of SEQ ID NO:159, and a sdCDR3 of SEQ ID NO:160; (j) a set of CDRs comprising a sdCDR1 of SEQ ID NO:162, a sdCDR2 of SEQ ID NO:163, and a sdCDR3 of SEQ ID NO:164; (k) a set of CDRs comprising a sdCDR1 of SEQ ID NO:166, a sdCDR2 of SEQ ID NO:167, and a sdCDR3 of SEQ ID NO:168; (1) a set of CDRs comprising a sdCDR1 of SEQ ID NO:170, a sdCDR2 of SEQ ID NO:171, and a sdCDR3 of SEQ ID NO:172; (m) a set of CDRs comprising a sdCDR1 of SEQ ID NO:174, a sdCDR2 of SEQ ID NO:175, and a sdCDR3 of SEQ ID NO:176; (n) a set of CDRs comprising a sdCDR1 of SEQ ID NO:178, a sdCDR2 of SEQ ID NO:179, and a sdCDR3 of SEQ ID NO:180; (o) a set of CDRs comprising a sdCDR1 of SEQ ID NO:182, a sdCDR2 of SEQ ID NO:183, and a sdCDR3 of SEQ ID NO:184; (p) a set of CDRs comprising a sdCDR1 of SEQ ID NO:186, a sdCDR2 of SEQ ID NO:187, and a sdCDR3 of SEQ ID NO:188; (q) a set of CDRs comprising a sdCDR1 of SEQ ID NO:190, a sdCDR2 of SEQ ID NO:191, and a sdCDR3 of SEQ ID NO:192; (r) a set of CDRs comprising a sdCDR1 of SEQ ID NO:194, a sdCDR2 of SEQ ID NO:195, and a sdCDR3 of SEQ ID NO:196; (s) a set of CDRs comprising a sdCDR1 of SEQ ID NO:198, a sdCDR2 of SEQ ID NO:199, and a sdCDR3 of SEQ ID NO:200; (t) a set of CDRs comprising a sdCDR1 of SEQ ID NO:202, a sdCDR2 of SEQ ID NO:203, and a sdCDR3 of SEQ ID NO:204; (u) a set of CDRs comprising a sdCDR1 of SEQ ID NO:206, a sdCDR2 of SEQ ID NO:207, and a sdCDR3 of SEQ ID NO:203; (v) a set of CDRs comprising a sdCDR1 of SEQ ID NO:210, a sdCDR2 of SEQ ID NO:211, and a sdCDR3 of SEQ ID NO:212; (w) a set of CDRs comprising a sdCDR1 of SEQ ID NO:214, a sdCDR2 of SEQ ID NO:215, and a sdCDR3 of SEQ ID NO:216; (x) a set of CDRs comprising a sdCDR1 of SEQ ID NO:218, a sdCDR2 of SEQ ID NO:219, and a sdCDR3 of SEQ ID NO:220; (y) a set of CDRs comprising a sdCDR1 of SEQ ID NO:222, a sdCDR2 of SEQ ID NO:223, and a sdCDR3 of SEQ ID NO:224; (z) a set of CDRs comprising a sdCDR1 of SEQ ID NO:226, a sdCDR2 of SEQ ID NO:227, and a sdCDR3 of SEQ ID NO:228; (aa) a set of CDRs comprising a sdCDR1 of SEQ ID NO:230, a sdCDR2 of SEQ ID NO:231, and a sdCDR3 of SEQ ID NO:232; (ab) a set of CDRs comprising a sdCDR1 of SEQ ID NO:234, a sdCDR2 of SEQ ID NO:235, and a sdCDR3 of SEQ ID NO:236; (ac) a set of CDRs comprising a sdCDR1 of SEQ ID NO:238, a sdCDR2 of SEQ ID NO:239, and a sdCDR3 of SEQ ID NO:240; and (ad) a set of CDRs comprising a sdCDR1 of SEQ ID NO:242, a sdCDR2 of SEQ ID NO:243, and a sdCDR3 with SEQ ID NO:244; (ae) SEQ ID NO:141; (af) SEQ ID NO:145; (ag) SEQ ID NO:149; (ah) SEQ ID NO:153; (ai) SEQ ID NO:157; (aj) SEQ ID NO:161; (ak) SEQ ID NO:165; (al) SEQ ID NO:169; (am) SEQ ID NO:173; (an) SEQ ID NO:177; (ao) SEQ ID NO:181; (ap) SEQ ID NO:185; (aq) SEQ ID NO:189; (ar) SEQ ID NO:193; (as) SEQ ID NO:197; (at) SEQ ID NO:201; (au) SEQ ID NO:205; (av) SEQ ID NO:209; (aw) SEQ ID NO:213; (ax) SEQ ID NO:217; (ay) SEQ ID NO:221; (az) SEQ ID NO:225; (ba) SEQ ID NO:229; (bb) SEQ ID NO:233; (bc) SEQ ID NO:237; and (bd) SEQ ID NO:241.
The fusion protein of any one of claims [00459]-[0027], wherein the sdABD-LyPD3 comprises an amino acid sequence selected from the group consisting of: (a) a set of CDRs comprising a sdCDR1 of SEQ ID NO:118, a sdCDR2 of SEQ ID NO:119 and a sdCDR3 of SEQ ID NO:120; (b) a set of CDRs comprising a sdCDR1 of SEQ ID NO:122, a sdCDR2 of SEQ ID NO:123 and a sdCDR3 of SEQ ID NO:124; (c) a set of CDRs comprising a sdCDR1 of SEQ ID NO:126, a sdCDR2 of SEQ ID NO:127 and a sdCDR3 of SEQ ID NO:128; (d) a set of CDRs comprising a sdCDR1 of SEQ ID NO:130, a sdCDR2 of SEQ ID NO:131, and a sdCDR3 of SEQ ID NO:132; (e) a set of CDRs comprising a sdCDR1 of SEQ ID NO:134, a sdCDR2 of SEQ ID NO:135, and a sdCDR3 of SEQ ID NO:136; (f) a set of CDRs comprising a sdCDR1 of SEQ ID NO:138, a sdCDR2 of SEQ ID NO:139, and a sdCDR3 of SEQ ID NO:140; (g) SEQ ID NO:117; (h) SEQ ID NO:121; (i) SEQ ID NO:125; (j) SEQ ID NO:129; (k) SEQ ID NO:133; and (1) SEQ ID NO:137.
In some embodiments, the sdABD-B7H3 comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:34 a sdCDR2 of SEQ ID NO:35 and a sdCDR3 of SEQ ID NO:36; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:38, a sdCDR2 of SEQ ID NO:39 and a sdCDR3 of SEQ ID NO:40; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:42, a sdCDR2 of SEQ ID NO:43 and a sdCDR3 of SEQ ID NO:44; (iv) a set of CDRs comprising a sdCDR1 of SEQ ID NO:46, a sdCDR2 of SEQ ID NO:47 and a sdCDR3 of SEQ ID NO:48; (v) a set of CDRs comprising a sdCDR1 of SEQ ID NO:50, a sdCDR2 of SEQ ID NO:51 and a sdCDR3 of SEQ ID NO:52; (vi) a set of CDRs comprising a sdCDR1 of SEQ ID NO:54, a sdCDR2 of SEQ ID NO:55 and a sdCDR3 of SEQ ID NO:56; (vii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:58, a sdCDR2 of SEQ ID NO:59 and a sdCDR3 of SEQ ID NO:60; (ix) SEQ ID NO:33; (x) SEQ ID NO:37; (xi) SEQ ID NO:41; (xii) SEQ ID NO:45; (xiii) SEQ ID NO:49; (xiv) SEQ ID NO:53; and (xv) SEQ ID NO:57.
In some embodiments, the sdABD-CA9 comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:102, a sdCDR2 of SEQ ID NO:103 and a sdCDR3 of SEQ ID NO:104; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:106, a sdCDR2 of SEQ ID NO:107 and a sdCDR3 of SEQ ID NO:108; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:110, a sdCDR2 of SEQ ID NO:111 and a sdCDR3 of SEQ ID NO:112; (iv) a set of CDRs comprising a sdCDR1 of SEQ ID NO:114, a sdCDR2 of SEQ ID NO:115 and a sdCDR3 of SEQ ID NO:116; (v) SEQ ID NO:101; (vi) SEQ ID NO:105; (vii) SEQ ID NO:109; and (viiii) SEQ ID NO:113.
In some embodiments, the sdABD-EGFR comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:2 a sdCDR2 of SEQ ID NO:3 and a sdCDR3 of SEQ ID NO:4; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:6, a sdCDR2 of SEQ ID NO:7 and a sdCDR3 of SEQ ID NO:8; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:10, a sdCDR2 of SEQ ID NO:11 and a sdCDR3 of SEQ ID NO:12; (iv) a set of CDRs comprising a sdCDR1 of SEQ ID NO:14, a sdCDR2 of SEQ ID NO:15 and a sdCDR3 of SEQ ID NO:16; (v) a set of CDRs comprising a sdCDR1 of SEQ ID NO:18, a sdCDR2 of SEQ ID NO:19 and a sdCDR3 of SEQ ID NO:20; (vi) SEQ ID NO:1; (vii) SEQ ID NO:5; (viii) SEQ ID NO:9; (ix) SEQ ID NO:13; and (x) SEQ ID NO:17.
In some embodiments, the sdABD-EpCAM comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:62 a sdCDR2 of SEQ ID NO:63 and a sdCDR3 of SEQ ID NO:64; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:66, a sdCDR2 of SEQ ID NO:67 and a sdCDR3 of SEQ ID NO:68; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:70, a sdCDR2 of SEQ ID NO:71 and a sdCDR3 of SEQ ID NO:72; (iv) a set of CDRs comprising a sdCDR1 of SEQ ID NO:74, a sdCDR2 of SEQ ID NO:75 and a sdCDR3 of SEQ ID NO:76; (v) a set of CDRs comprising a sdCDR1 of SEQ ID NO:496, a sdCDR2 of SEQ ID NO:497 and a sdCDR3 of SEQ ID NO:498; (vi) SEQ ID NO:61; (vii) SEQ ID NO:65; (viii) SEQ ID NO:69; (ix) SEQ ID NO:73; and (x) SEQ ID NO:495.
In some embodiments, the sdABD-FOLR1 comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:22 a sdCDR2 of SEQ ID NO:23 and a sdCDR3 of SEQ ID NO:24; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:26, a sdCDR2 of SEQ ID NO:27 and a sdCDR3 of SEQ ID NO:28; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:30, a sdCDR2 of SEQ ID NO:31 and a sdCDR3 of SEQ ID NO:32; (iv) SEQ ID NO:21; (v) SEQ ID NO:25; and (vi) SEQ ID NO:29.
In some embodiments, the sdABD-Trop2 comprises an amino acid sequence selected from the group consisting of: (i) a set of CDRs comprising a sdCDR1 of SEQ ID NO:78, a sdCDR2 of SEQ ID NO:79 and a sdCDR3 of SEQ ID NO:80; (ii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:82, a sdCDR2 of SEQ ID NO:83 and a sdCDR3 of SEQ ID NO:84; (iii) a set of CDRs comprising a sdCDR1 of SEQ ID NO:86, a sdCDR2 of SEQ ID NO:87 and a sdCDR3 of SEQ ID NO:88; (iv) a set of CDRs comprising a sdCDR1 of SEQ ID NO:90, a sdCDR2 of SEQ ID NO:91, and a sdCDR3 of SEQ ID NO:92; (v) a set of CDRs comprising a sdCDR1 of SEQ ID NO:94, a sdCDR2 of SEQ ID NO:95, and a sdCDR3 of SEQ ID NO:96; (vi) a set of CDRs comprising a sdCDR1 of SEQ ID NO:98, a sdCDR2 of SEQ ID NO:99, and a sdCDR3 of SEQ ID NO:100; (vii) SEQ ID NO:77; (viii) SEQ ID NO:81; (ix) SEQ ID NO:85; (x) SEQ ID NO:89; (xi) SEQ ID NO:93; and (xii) SEQ ID NO:97.
In some embodiments, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo variable light domain is N-terminal to the pseudo variable heavy domain.
In some embodiments, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In some embodiments, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo variable light domain is N-terminal to the pseudo variable heavy domain.
In some embodiments, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In some embodiments, the third sdABD that bind to HSA has an amino acid sequence comprising: (a) set of CDRs selected from the group consisting of (i) a sdCDR1 of SEQ ID NO:246, a sdCDR2 of SEQ ID NO:247, and a sdCDR3 of SEQ ID NO:248, and (ii) a sdCDR1 of SEQ ID NO:250, a sdCDR2 of SEQ ID NO:251, and a sdCDR3 of SEQ ID NO:252; or (b) an amino acid sequence selected from the group consisting of SEQ ID NO:245 and SEQ ID NO:249.
In some embodiments, the cleavable linker comprises a cleavage domain sequence selected from the group consisting of SEQ ID NOS:339-408 and 532-535.
In some embodiments, the cleavable linker is cleaved by a human protease selected from the group consisting of MMP2, MMP9, meprin A, meprin B, cathepsin S, capthepsin K, capthesin L, granzyme B, uPA, kallekriein7, matriptase, and thrombin.
In some embodiments, the fusion proteins comprises an amino acid sequence selected from the group consisting of SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, and SEQ ID NO:458.
Provided herein is a nucleic acid encoding any of the fusion proteins described. Provided herein is an expression vector comprising any of the nucleic acids described. Provided herein is a host cell comprising any of the expression vectors described
In some aspects, provided is a method of making a fusion protein of the present disclosure comprising: (i) culturing the host cell described under conditions wherein the fusion protein is expressed and (ii) recovering the fusion protein.
In some aspects, provided is a single domain antigen binding domain that binds human LyPD3 (sdABD-LyPD3) comprising (i) an amino acid sequence selected from the group consisting of SEQ ID NO:117, SEQ ID NO:121, SEQ ID NO:125, SEQ ID NO:129, SEQ ID NO:133 and, SEQ ID NO:137 or (ii) an amino acid sequence comprising a set of CDRs selected from the group consisting of: (a) a sdCDR1 of SEQ ID NO:118, a sdCDR2 of SEQ ID NO:119 and a sdCDR3 of SEQ ID NO:120; (b) a sdCDR1 of SEQ ID NO:122, a sdCDR2 of SEQ ID NO:123 and a sdCDR3 of SEQ ID NO:124; (c) a sdCDR1 of SEQ ID NO:126, a sdCDR2 of SEQ ID NO:127 and a sdCDR3 of SEQ ID NO:128; (d) a sdCDR1 of SEQ ID NO:130, a sdCDR2 of SEQ ID NO:131, and a sdCDR3 of SEQ ID NO:132; (e) a sdCDR1 of SEQ ID NO:134, a sdCDR2 of SEQ ID NO:135, and a sdCDR3 of SEQ ID NO:136; and (f) a sdCDR1 of SEQ ID NO:138, a sdCDR2 of SEQ ID NO:139, and a sdCDR3 of SEQ ID NO:140.
Also provided is a nucleic acid encoding any of the single domain antigen binding domains (sdABDs) described. Also provided is an expression vector comprising any of the nucleic acids. Provided is a host cell comprising any of the expression vectors described.
In some aspects, provided is a method of making a single domain antigen binding domain (sdABD) comprising (a) culturing any of the host cells described herein under conditions wherein the sdABD is expressed and (b) recovering the sdABD.
Also provided is a pharmaceutical composition comprising any of the fusion proteins described or any of the single domain antigen binding domains (sdABDs) described.
In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
In some aspects, provided is a method of treating cancer in a subject comprising administering any of the fusion proteins described, any of the single domain antigen binding domains (sdABDs) described, or any of the pharmaceutical compositions of the present disclosure.
The present invention is directed to methods of reducing the toxicity and side effects of bispecific antibodies (including antibody-like functional proteins) that bind to important physiological targets such as CD3 and tumor antigens. Many antigen binding proteins, such as antibodies, can have significant side effects by targeting normal tissues, and thus there is a need to only activate the binding capabilities of a therapeutic molecule in the vicinity of the disease tissue, to avoid normal tissue interactions. Accordingly, the present invention is directed to multivalent conditionally effective (“MCE”) proteins that have a number of functional protein domains. In general, one of these domains is an antigen binding domain (ABD) that will bind a target tumor antigen (TTA), and another is an ABD that will bind a T-cell antigen such as CD3 under certain conditions. Additionally, the MCE proteins also include one or more protease cleavage sites. That is, the therapeutic molecules are made in a “pro-drug” like format, wherein the CD3 binding domain is inactive until exposed to a tumor environment. The tumor environment contains proteases, such that upon exposure to the protease, the prodrug is cleaved and becomes active.
This is generally accomplished herein by using proteins that include a “pseudo” variable heavy domain and a “pseudo” variable light domain directed to the T-cell antigen such as CD3, that restrain the CD3 Fvs of the MCE into an inactive format as is discussed herein. As the TTA targets the MCE into the proximity of the tumor, the MCE is thus exposed to the protease. Upon cleavage, the active variable heavy domain and active light domain are now able to pair to form one or more active ABDs to CD3 and thus recruit T cells to the tumor, resulting in treatment.
In general, the CD3 binding domain (“Fv”) is in a constrained format, wherein the linker between the active variable heavy domain and the active variable light domain that traditionally form an Fv is too short to allow the two active variable domains to bind each other; this is referred to as “constrained linker”; these can be constrained and cleavable (CCL, as used in Format 1) or constrained and not cleavable (CNCL, as used in Format 2). Rather, in the prodrug (e.g., uncleaved) format, the prodrug polypeptide also comprises a “pseudo Fv domain”. The pseudo Fv domain comprises a variable heavy and light domain, with standard framework regions, but “inert” or “inactive” CDRs. The pseudo Fv domain also has a constrained linker between the inactive variable heavy and inactive variable light domains. Since neither Fv nor pseudo Fv domains can self-assemble due to the steric constraints, there is an intramolecular assembly that pairs the aVL with the iVH and the aVH with the iVL, due to the affinity of the framework regions of each. However, due to the “inert” CDRs of the pseudo domain, the resulting ABDs will not bind CD3, thus preventing toxicities outside the diseased tissue, such as a tumor. However, in the presence of proteases that are in or near the tumor, the prodrug construct is cleaved such that the pseudo-Fv domain is released from the surface and thus allows the “real” variable heavy and variable light domains to associate intermolecularly (e.g. two cleaved constructs come together), thus triggering active CD3 binding and the resulting tumor efficacy. These constructs are generally referred to herein as COnditional Bispecific Redirected Activation constructs, or “COBRAs™”. The stability of the intramolecular assembly is shown by the conditionality experiments herein, whereby in the absence of protease, the uncleaved constructs have no activity (e.g. no active CD3 binding domain is formed).
Interestingly, for ease of description, while these constructs are all referred to herein as “constrained”, additional work shows that the intramolecular assembly is favored even if one of the Fv domains is not constrained, e.g. one of the domains can have a longer, flexible linker. That is, as shown in the
The constructs and formats of the invention are variations over embodiments described in WO2017/156178, WO2019/051102, WO2020/181140, US2019/0076524, and US2020/0347132, hereby expressly incorporated by reference in their entireties. As shown in
To solve this issue, the present invention provides for four separate types of constructs to accomplish this conditional activation. The prodrug activation can happen in one of four general ways, as is generally shown in the Figures. In
In an alternate embodiment, the prodrug construct is shown in
In addition to the “single chain protein” COBRA formats discussed above, where all of the components are contained on a single amino acid sequence, there are also constructs that rely on two proteins “hemi-COBRAs”, which act in pairs, as shown in
Furthermore, the invention provides “format 4” constructs as well, as depicted in
Accordingly, the formats and constructs of the invention find use in the treatment of disease.
In order that the application may be more completely understood, several definitions are set forth below. Such definitions are meant to encompass grammatical equivalents.
By “amino acid” and “amino acid identity” as used herein is meant one of the 20 naturally occurring amino acids or any non-natural analogues that may be present at a specific, defined position. In many embodiments, “amino acid” means one of the 20 naturally occurring amino acids. By “protein” herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
By “amino acid modification” herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence or an alteration to a moiety chemically linked to a protein. For example, a modification may be an altered carbohydrate or PEG structure attached to a protein. For clarity, unless otherwise noted, the amino acid modification is always to an amino acid coded for by DNA, e.g. the 20 amino acids that have codons in DNA and RNA. The preferred amino acid modification herein is a substitution.
By “amino acid substitution” or “substitution” herein is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence with a different amino acid. In particular, in some embodiments, the substitution is to an amino acid that is not naturally occurring at the particular position, either not naturally occurring within the organism or in any organism. For clarity, a protein which has been engineered to change the nucleic acid coding sequence but not change the starting amino acid (for example exchanging CGG (encoding arginine) to CGA (still encoding arginine) to increase host organism expression levels) is not an “amino acid substitution”; that is, despite the creation of a new gene encoding the same protein, if the protein has the same amino acid at the particular position that it started with, it is not an amino acid substitution.
By “amino acid insertion” or “insertion” as used herein is meant the addition of an amino acid sequence at a particular position in a parent polypeptide sequence.
By “amino acid deletion” or “deletion” as used herein is meant the removal of an amino acid sequence at a particular position in a parent polypeptide sequence.
The polypeptides of the invention specifically bind to CD3 and target tumor antigens (TTAs) such as target cell receptors, as outlined herein. “Specific binding” or “specifically binds to” or is “specific for” a particular antigen or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.
Specific binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KD for an antigen or epitope of at least about 10-4 M, at least about 10-5 M, at least about 10-6 M, at least about 10-7 M, at least about 10-8 M, at least about 10-9 M, alternatively at least about 10-10 M, at least about 10-11 M, at least about 10-12 M, or greater, where KD refers to a dissociation rate of a particular antibody-antigen interaction. Typically, an antibody that specifically binds an antigen will have a KD that is 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for a control molecule relative to the antigen or epitope.
Also, specific binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KA or Ka for an antigen or epitope of at least 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for the epitope relative to a control, where KA or Ka refers to an association rate of a particular antibody-antigen interaction. Binding affinity is generally measured using a Biacore assay or Octet as is known in the art.
By “parent polypeptide” or “precursor polypeptide” (including Fc parent or precursors) as used herein is meant a polypeptide that is subsequently modified to generate a variant. Said parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide. Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it. Accordingly, by “parent Fc polypeptide” as used herein is meant an unmodified Fc polypeptide that is modified to generate a variant, and by “parent antibody” as used herein is meant an unmodified antibody that is modified to generate a variant antibody.
By “position” as used herein is meant a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example the EU index for antibody numbering.
By “target antigen” as used herein is meant the molecule that is bound specifically by the variable region of a given antibody. A target antigen may be a protein, carbohydrate, lipid, or other chemical compound. A range of suitable exemplary target antigens are described herein.
By “target cell” as used herein is meant a cell that expresses a target antigen. Generally, for the purposes of the invention, target cells are either tumor cells that express TTAs or T cells that express the CD3 antigen.
By “Fv” or “Fv domain” or “Fv region” as used herein is meant a polypeptide that comprises the VL and VH domains of an antigen binding domain, generally from an antibody. Fv domains usually form an “antigen binding domain” or “ABD” as discussed herein, if they contain active VH and VL domains (although in some cases, an Fv containing a constrained linker is used, such that an active ABD isn’t formed prior to cleavage). As discussed below, Fv domains can be organized in a number of ways in the present invention, and can be “active” or “inactive”, such as in a scFv format, a constrained Fv format, a pseudo Fv format, etc. It should be understood that in the present invention, in some cases an Fv domain is made up of a VH and VL domain on a single polypeptide chain, such as shown in
By “variable domain” herein is meant the region of an immunoglobulin that comprises one or more Ig domains substantially encoded by any of the Vκ, Vλ, and/or VH genes that make up the kappa, lambda, and heavy chain immunoglobulin genetic loci respectively. In some cases, a single variable domain, such as a sdFv (also referred to herein as sdABD) can be used.
In embodiments utilizing both variable heavy (VH) and variable light (VL) domains, each VH and VL is composed of three hypervariable regions (“complementary determining regions,” “CDRs”) and four “framework regions”, or “FRs”, arranged from amino-terminus to carboxy-terminus in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Thus, the VH domain has the structure vhFR1-vhCDR1-vhFR2-vhCDR2-vhFR3-vhCDR3-vhFR4 and the VL domain has the structure v1FR1-v1CDR1-v1FR2-vC1DR2-v1FR3-vlCDR3-vlFR4. As is more fully described herein, the vhFR regions and the v1FR regions self-assemble to form Fv domains. In general, in the prodrug formats of the invention, there are “constrained Fv domains” wherein the VH and VL domains cannot self associate, and “pseudo Fv domains” for which the CDRs do not form antigen binding domains when self associated.
The hypervariable regions confer antigen binding specificity and generally encompasses amino acid residues from about amino acid residues 24-34 (LCDR1; “L” denotes light chain), 50-56 (LCDR2) and 89-97 (LCDR3) in the light chain variable region and around about 31-35B (HCDR1; “H” denotes heavy chain), 50-65 (HCDR2), and 95-102 (HCDR3) in the heavy chain variable region; Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) and/or those residues forming a hypervariable loop (e.g. residues 26-32 (LCDR1), 50-52 (LCDR2) and 91-96 (LCDR3) in the light chain variable region and 26-32 (HCDR1), 53-55 (HCDR2) and 96-101 (HCDR3) in the heavy chain variable region; Chothia and Lesk (1987) J. Mol. Biol. 196:901-917. Specific CDRs of the invention are described below.
As will be appreciated by those in the art, the exact numbering and placement of the CDRs can be different among different numbering systems. However, it should be understood that the disclosure of a variable heavy and/or variable light sequence includes the disclosure of the associated (inherent) CDRs. Accordingly, the disclosure of each variable heavy region is a disclosure of the vhCDRs (e.g. vhCDR1, vhCDR2 and vhCDR3) and the disclosure of each variable light region is a disclosure of the v1CDRs (e.g. vlCDR1, vlCDR2 and vlCDR3).
A useful comparison of CDR numbering is as below, see Lafranc et al., Dev. Comp. Immunol. 27(1):55-77 (2003):
Throughout the present specification, the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g, Kabat et al., supra (1991)).
The present invention provides a large number of different CDR sets. In this case, a “full CDR set” in the context of the anti-CD3 component comprises the three variable light and three variable heavy CDRs, e.g. a vlCDR1, vlCDR2, vlCDR3, vhCDR1, vhCDR2 and vhCDR3. As will be appreciated by those in the art, each set of CDRs, the VH and VL CDRs, can bind to antigens, both individually and as a set. For example, in constrained Fv domains, the vhCDRs can bind, for example to CD3 and the vlCDRs can bind to CD3, but in the constrained format they cannot bind to CD3.
In the context of a single domain ABD (“sdABD”) such as are generally used herein to bind to target tumor antigens (TTA), a CDR set is only three CDRs; these are sometimes referred to in the art as “VHH” domains as well.
These CDRs can be part of a larger variable light or variable heavy domain, respectfully. In addition, as more fully outlined herein, the variable heavy and variable light domains can be on separate polypeptide chains or on a single polypeptide chain in the case of scFv sequences, depending on the format and configuration of the moieties herein.
The CDRs contribute to the formation of the antigen-binding, or more specifically, epitope binding sites. “Epitope” refers to a determinant that interacts with a specific antigen binding site in the variable regions known as a paratope. Epitopes are groupings of molecules such as amino acids or sugar side chains and usually have specific structural characteristics, as well as specific charge characteristics. A single antigen may have more than one epitope.
The epitope may comprise amino acid residues directly involved in the binding (also called immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked by the specific antigen binding peptide; in other words, the amino acid residue is within the footprint of the specific antigen binding peptide.
Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. Conformational and nonconformational epitopes may be distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Antibodies that recognize the same epitope can be verified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen, for example “binning.” As outlined below, the invention not only includes the enumerated antigen binding domains and antibodies herein, but those that compete for binding with the epitopes bound by the enumerated antigen binding domains.
The variable heavy and variable light domains of the invention can be “active” or “inactive”.
As used herein, “inactive VH” (“iVH”) and “inactive VL” (“iVL”) refer to components of a pseudo Fv domain, which, when paired with their cognate VL or VH partners, respectively, form a resulting VH/VL pair that does not specifically bind to the antigen to which the “active” VH or “active” VL would bind were it bound to an analogous VL or VH, which was not “inactive”. Exemplary “inactive VH” and “inactive VL” domains are formed by mutation of a wild type VH or VL sequence as more fully outlined below. Exemplary mutations are within CDR1, CDR2 or CDR3 of VH or VL. An exemplary mutation includes placing a domain linker within CDR2, thereby forming an “inactive VH” or “inactive VL” domain. In contrast, an “active VH” or “active VL” is one that, upon pairing with its “active” cognate partner, i.e., VL or VH, respectively, is capable of specifically binding to its target antigen. Thus, it should be understood that a pseudo Fv can be a VH/iVL pair, a iVH/VL pair, or a iVH/iVL pair.
In contrast, as used herein, the term “active” refers to a CD3 binding domain that is capable of specifically binding to CD3. This term is used in two contexts: (a) when referring to a single member of an Fv binding pair (i.e., VH or VL), which is of a sequence capable of pairing with its cognate partner and specifically binding to CD3; and (b) the pair of cognates (i.e., VH and VL) of a sequence capable of specifically binding to CD-. An exemplary “active” VH, VL or VH/VL pair is a wild type or parent sequence.
“CD-x” refers to a cluster of differentiation (CD) protein. In exemplary embodiments, CD-x is selected from those CD proteins having a role in the recruitment or activation of T-cells in a subject to whom a polypeptide construct of the invention has been administered. In an exemplary embodiment, CD-x is CD3, the sequence of which is shown in
The term “binding domain” characterizes, in connection with the present invention, a domain which (specifically) binds to/interacts with/recognizes a given target epitope or a given target site on the target molecules (antigens), for example: EGFR and CD3, respectively. The structure and function of the target antigen binding domain (recognizing EGFR), and preferably also the structure and/or function of the CD3 binding domain (recognizing CD3), is/are based on the structure and/or function of an antibody, e.g. of a fulllength or whole immunoglobulin molecule, including sdABDs. According to the invention, the target antigen binding domain is generally characterized by the presence of three CDRs that bind the target tumor antigen (generally referred to in the art as variable heavy domains, although no corresponding light chain CDRs are present). Alternatively, ABDs to TTAs can include three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and/or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region). The CD3 binding domain preferably also comprises at least the minimum structural requirements of an antibody which allow for the target binding. More preferably, the CD3 binding domain comprises at least three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and/or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region). It is envisaged that in exemplary embodiments the target antigen and/or CD3 binding domain is produced by or obtainable by phage-display or library screening methods.
By “domain” as used herein is meant a protein sequence with a function, as outlined herein. Domains of the invention include tumor target antigen binding domains (TTA domains), variable heavy domains, variable light domains, scFv domains, linker domains, and half life extension domains.
By “domain linker” herein is meant an amino acid sequence that joins two domains as outlined herein. Domain linkers can be cleavable linkers, constrained cleavable linkers, non-cleavable linkers, constrained non-cleavable linkers, scFv linkers, etc.
By “cleavable linker” (“CL”) herein is meant an amino acid sequence that can be cleaved by a protease, preferably a human protease in a disease tissue as outlined herein. Cleavable linkers generally are at least 3 amino acids in length, with from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acids finding use in the invention, depending on the required flexibility. A number of cleavable linker sequences are found in
By “non cleavable linker” (“NCL”) herein is meant an amino acid sequence that cannot be cleaved by a human protease under normal physiological conditions.
By “constrained cleavable linker” (“CCL”) herein is meant a short polypeptide that contains a protease cleavage site (as defined herein) that joins two domains as outlined herein in such a manner that the two domains cannot significantly interact with each other until after they reside on different polypeptide chains, e.g. after cleavage. When the CCL joins a VH and a VL domain as defined herein, the VH and VL cannot self- assemble to form a functional Fv prior to cleavage due to steric constraints in an intramolecular way (although they may assemble into pseudo Fv domains in an intermolecular way). Upon cleavage by the relevant protease, the VH and VL can assemble to form an active antigen binding domain in an intermolecular way. In general, CCLs are less than 10 amino acids in length, with 9, 8, 7, 6, 5 and 4 amino acids finding use in the invention. In general, protease cleavage sites generally are at least 4+ amino acids in length to confer sufficient specificity, as is shown in
By “constrained non-cleavable linker” (“CNCL”) herein is meant a short polypeptide that that joins two domains as outlined herein in such a manner that the two domains cannot significantly interact with each other, and that is not significantly cleaved by human proteases under physiological conditions.
By “constrained Fv domain” herein is meant an Fv domain that comprises an active variable heavy domain and an active variable light domain, linked covalently with a constrained linker as outlined herein, in such a way that the active heavy and light variable domains cannot intramolecularly interact to form an active Fv that will bind an antigen such as CD3. Thus, a constrained Fv domain is one that is similar to an scFv but is not able to bind an antigen due to the presence of a constrained linker (although they may assemble intermolecularly with inert variable domains to form pseudo Fv domains).
By “pseudo Fv domain” herein is meant a domain that comprises a pseudo or inactive variable heavy domain or a pseudo or inactive variable light domain, or both, linked using a domain linker (which can be cleavable, constrained, non-cleavable, non-constrained, etc.). The iVH and iVL domains of a pseudo Fv domain do not bind to a human antigen when either associated with each other (iVH/iVL) or when associated with an active VH or VL; thus iVH/iVL, iVH/VL and iVL/VH Fv domains do not appreciably bind to a human protein, such that these domains are inert in the human body.
By “single chain Fv” or “scFv” herein is meant a variable heavy (VH) domain covalently attached to a variable light (VL) domain, generally using a domain linker as discussed herein, to form a scFv or scFv domain. A scFv domain can be in either orientation from N- to C-terminus (VH -linker- VL or VL-linker-VH).
By “single domain Fv”, “sdFv” or “sdABD” herein is meant an antigen binding domain that only has three CDRs, generally based on camelid antibody technology. See: Protein Engineering 9(7):1129-35 (1994); Rev Mol Biotech 74:277-302 (2001); Ann Rev Biochem 82:775-97 (2013). As outlined herein, there are two general types of sdABDs used herein: sdABDs that bind to TTAs, and are annotated as such (sdABD-TTA for the generic term, or sdABD-EGFR for one that binds to EGFR, sdABD-FOLR1 for one that binds to FOLR1, etc.) and sdABDs that bind to HSA (“sdABD-HSA” or “sdABD(½)”.
By “protease cleavage site” refers to the amino acid sequence recognized and cleaved by a protease. Suitable protease cleavage sites are outlined below and shown in
As used herein, “protease cleavage domain” refers to the peptide sequence incorporating the “protease cleavage site” and any linkers between individual protease cleavage sites and between the protease cleavage site(s) and the other functional components of the constructs of the invention (e.g., VH, VL, iVH, iVL, target antigen binding domain(s), half-life extension domain, etc.). As outlined herein, a protease cleavage domain may also include additional amino acids if necessary, for example to confer flexibility.
The term “COBRA™” and “conditional bispecific redirected activation” refers to a bispecific conditionally effective protein that has a number of functional protein domains. In some embodiments, one of the functional domains is an antigen binding domain (ABD) that binds a target tumor antigen (TTA). In certain embodiments, another domain is an ABD that binds to a T cell antigen under certain conditions. The T cell antigen includes but is not limited to CD3. The term “hemi-COBRA™” refers to a conditionally effective protein that can bind a T cell antigen when a variable heavy chain of a hemi-COBRA can associate to a variable light chain of another hemi-COBRA™ (a complementary hemi-COBRA™) due to innate self-assembly when concentrated on the surface of a target expressing cell.
The fusion proteins of the invention have a number of different components, generally referred to herein as domains that are linked together in a variety of ways. Some of the domains are binding domains, that each bind to a target antigen (e.g. a TTA or CD3, for example). As they bind to more than one antigen, they are referred to herein as “multispecific”; for example, a prodrug construct of the invention may bind to a TTA and CD3, and thus are “bispecific”. A protein can also have higher specificities; for example, if the first αTTA binds to EGFR, the second to EpCAM and there is an anti-CD3 binding domain, this would be a “trispecific” molecule. Similarly, the addition of an anti-HSA binding domain to this construct would be “tetraspecific”, as shown in
As will be appreciated by those in the art, the proteins of the invention can have different valencies as well as be multispecific. That is, proteins of the invention can bind a target with more than one binding site; for example, Pro186 is bivalent for EGFR.
The proteins of the invention can include CD3 antigen binding domains arranged in a variety of ways as outlined herein, tumor target antigen binding domains, half-life extension domains, linkers, etc.
The specificity of the response of T cells is mediated by the recognition of antigen (displayed in context of a major histocompatibility complex, MHC) by the T cell receptor complex. As part of the T cell receptor complex, CD3 is a protein complex that includes a CD3γ (gamma) chain, a CD3δ (delta) chain, two CD3e (epsilon) chains and two CD3ζ (zeta) chains, which are present at the cell surface. CD3 molecules associate with the α (alpha) and β (beta) chains of the T cell receptor (TCR) to comprise the TCR complex. Clustering of CD3 on T cells, such as by Fv domains that bind to CD3 leads to T cell activation similar to the engagement of the T cell receptor but independent of its clonal-typical specificity.
However, as is known in the art, CD3 activation can cause a number of toxic side effects, and accordingly the present invention is directed to providing active CD3 binding of the polypeptides of the invention only in the presence of tumor cells, where specific proteases are found, that then cleave the prodrug polypeptides of the invention to provide an active CD3 binding domain. Thus, in the present invention, binding of an anti-CD3 Fv domain to CD3 is regulated by a protease cleavage domain which restricts binding of the CD3 Fv domain to CD3 only in the microenvironment of a diseased cell or tissue with elevated levels of proteases, for example in a tumor microenvironment as is described herein.
Accordingly, the present invention provides two sets of VH and VL domains, an active set (VH and VL) and an inactive set (inactive VH and inactive VL; also referred to as “iVH” and “iVL”, respectively) with all four being present in the prodrug construct. The construct is formatted such that the VH and VL set cannot self-associate, but rather associates with an inactive partner, e.g. iVH and VL and iVL and VH as is shown herein.
There are a number of suitable active CDR sets, and/or VH and VL domains, that are known in the art that find use in the present invention. For example, the CDRs and/or VH and VL domains are derived from known anti-CD3 antibodies, such as, for example, muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), visilizumab (Nuvion), SP34 or I2C, TR-66 or X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1 and WT-31.
In one embodiment, the VH and VL sequences that form an active Fv domain that binds to human CD3 are shown in
The inactive iVH and iVL domains contain “regular” framework regions (FRs) that allow association, such that an inactive variable domain will associate with an active variable domain, rendering the pair inactive, e.g. unable to bind CD3.
As will be appreciated by those in the art, there are a number of “inactive” variable domains that find use in the invention. Basically, any variable domain with human framework regions that allows self-assembly with another variable domain, no matter what amino acids are in the CDR location in the variable region, can be used. For clarity, the inactive domains are said to include CDRs, although technically the inactive variable domains do not confer binding capabilities.
As will be appreciated in the art, it is generally straightforward to generate inactive VH or VL domains, and can be done in a variety of ways. In some embodiments, the generation of inactive variable domains is generally done by altering one or more of the CDRs of an active Fv, including making changes in one or more of the three CDRs of an active variable domain. This can be done by making one or more amino acid substitutions at functionally important residues in one or more CDRs, replacing some or all CDR residues with random sequences, replacing one or more CDRs with tag or flag sequences, and/or swapping CDRs and/or variable regions with those from an irrelevant antibody (one directed to a different organism’s protein for example.
In some cases, only one of the CDRs in a variable region can be altered to render it inactive, although other embodiments include alterations in one, two, three, four, five or six CDRs.
In some cases, the inactive domains can be engineered to promote selective binding in the prodrug format, to encourage formation of intramolecular iVH-VL and VH-iVL domains prior to cleavage (over, for example, intermolecular pair formation). See for example Igawa et al., Protein Eng. Des. Selection 23(8):667-677 (2010), hereby expressly incorporated by reference in its entirety and specifically for the interface residue amino acid substitutions.
In certain embodiments, the CD3 binding domain of the polypeptide constructs described herein exhibit not only potent CD3 binding affinities with human CD3, but show also excellent cross reactivity with the respective cynomolgus monkey CD3 proteins. In some instances, the CD3 binding domain of the polypeptide constructs is cross-reactive with CD3 from cynomolgus monkey. In certain instances, human:cynomolgous KD ratios for CD3 are between 5 and 0.2.
In some embodiments, the CD3 binding domain of the antigen binding protein can be any domain that binds to CD3 including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some instances, it is beneficial for the CD3 binding domain to be derived from the same species in which the antigen binding protein will ultimately be used in. For example, for use in humans, it may be beneficial for the CD3 binding domain of the antigen binding protein to comprise human or humanized residues from the antigen binding domain of an antibody or antibody fragment.
Thus, in one aspect, the antigen-binding domain comprises a humanized or human binding domain. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a humanized or human anti-CD3 binding domain described herein, and/or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a humanized or human anti-CD3 binding domain described herein, e.g., a humanized or human anti-CD3 binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.
In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human light chain variable region specific to CD3 where the light chain variable region specific to CD3 comprises human or non-human light chain CDRs in a human light chain framework region. In certain instances, the light chain framework region is a λ (lambda) light chain framework. In other instances, the light chain framework region is a κ (kappa) light chain framework.
In some embodiments, one or more CD3 binding domains are humanized or fully human. In some embodiments, one or more activated CD3 binding domains have a KD binding of 1000 nM or less to CD3 on CD3 expressing cells. In some embodiments, one or more activated CD3 binding domains have a KD binding of 100 nM or less to CD3 on CD3 expressing cells. In some embodiments, one or more activated CD3 binding domains have a KD binding of 10 nM or less to CD3 on CD3 expressing cells. In some embodiments, one or more CD3 binding domains have crossreactivity with cynomolgus CD3. In some embodiments, one or more CD3 binding domains comprise an amino acid sequence provided herein.
In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human heavy chain variable region specific to CD3 where the heavy chain variable region specific to CD3 comprises human or non-human heavy chain CDRs in a human heavy chain framework region.
In one embodiment, the anti-CD3 binding domain is an Fv comprising a light chain and a heavy chain of an amino acid sequence provided herein. In an embodiment, the anti-CD3 binding domain comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of a light chain variable region provided herein, or a sequence with 95-99% identity with an amino acid sequence provided herein; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of a heavy chain variable region provided herein, or a sequence with 95-99% identity to an amino acid sequence provided herein. In one embodiment, the humanized or human anti-CD3 binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, is attached to a heavy chain variable region comprising an amino acid sequence described herein, via a scFv linker. The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region- scFv linker-heavy chain variable region or heavy chain variable region- scFv linker-light chain variable region.
In some embodiments, CD3 binding domain of an antigen binding protein has an affinity to CD3 on CD3 expressing cells with a KD of 1000 nM or less, 100 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CD3 binding domain of an antigen binding protein has an affinity to CD3ε with a KD of 1000 nM or less, 100 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In further embodiments, CD3 binding domain of an antigen binding protein has low affinity to CD3, i.e., about 100 nM or greater.
The affinity to bind to CD3 can be determined, for example, by the ability of the antigen binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate; displayed on a microbial cell surface; in solution; etc., as is known in the art, generally using Biacore or Octet assays. The binding activity of the antigen binding protein itself or its CD3 binding domain of the present disclosure to CD3 can be assayed by immobilizing the ligand (e.g., CD3) or the antigen binding protein itself or its CD3 binding domain, to a bead, substrate, cell, etc. Agents can be added in an appropriate buffer and the binding partners incubated for a period of time at a given temperature. After washes to remove unbound material, the bound protein can be released with, for example, SDS, buffers with a high pH, and the like and analyzed, for example, by Surface Plasmon Resonance (SPR).
In many embodiments, preferred active and inert binding domains are those shown in
As shown in
As shown in
In addition to the described CD3 and half-life extension domains, the polypeptide constructs described herein also comprise target domains that bind to one or more target antigens or one or more regions on a single target antigen. It is contemplated herein that a polypeptide construct of the invention is cleaved, for example, in a disease-specific microenvironment or in the blood of a subject at the protease cleavage domain and that each target antigen binding domain will bind to a target antigen on a target cell, thereby activating the CD3 binding domain to bind a T cell. In general, the TTA binding domains can bind to their targets before protease cleavage, so they can “wait” on the target cell to be activated as T-cell engagers. At least one target antigen is involved in and/or associated with a disease, disorder or condition. Exemplary target antigens include those associated with a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease. In some embodiments, a target antigen is a tumor antigen expressed on a tumor cell. Alternatively, in some embodiments, a target antigen is associated with a pathogen such as a virus or bacterium. At least one target antigen may also be directed against healthy tissue.
In some embodiments, a target antigen is a cell surface molecule such as a protein, lipid or polysaccharide. In some embodiments, a target antigen is a on a tumor cell, virally infected cell, bacterially infected cell, damaged red blood cell, arterial plaque cell, or fibrotic tissue cell.
Preferred embodiments of the invention utilize sdABDs as the targeting domains. These are preferred over scFv ABDs, since the addition of other VH and VL domains into a construct of the invention may complicate the formation of pseudo Fv domains.
In some embodiments, the pro-drug constructs of the invention utilize a single TTA binding domain, such as generally depicted in
In some embodiments, particularly in the Format 1 and Format 2 constructs, the pro-drug constructs of the invention utilize two TTA ABDs, again preferably in the sdABD-TTA format. When dual targeting domains are used, they can bind to the same epitope of the same TTA. For example, as discussed herein, many of the constructs herein utilize two identical targeting domains. In some embodiments, two targeting domains can be used that bind to different epitopes of the same TTA, for example as shown in
Polypeptide constructs contemplated herein include at least one antigen binding domain, wherein the antigen binding domain binds to at least one target antigen. In some embodiments, the target antigen binding domains specifically bind to a cell surface molecule. In some embodiments, the target antigen binding domains specifically bind to a tumor antigen. In some embodiments, the target antigen binding domains specifically and independently bind to a tumor target antigen (“TTA”) selected from at least one of EpCAM, EGFR, HER-2, LyPD3, B7H3, CA9, Trop2 and FOLR1. As discussed below, these can be combined in a variety of ways.
As shown in
In some embodiments, the sdABD-EGFR (e.g., sdABD-αEGFR1) has a sdCDR1 with SEQ ID NO:2 a sdCDR2 with SEQ ID NO:3 and a sdCDR3 with SEQ ID NO:4. In some cases, the sdABD-EGFR has the amino acid sequence of SEQ ID NO:1, as provided in
In some embodiments, the sdABD-EGFR (e.g., sdABD-αEGFR2) has a sdCDR1 with SEQ ID NO:6, a sdCDR2 with SEQ ID NO:7 and a sdCDR3 with SEQ ID NO:8. In some cases, the sdABD-EGFR has the amino acid sequence of SEQ ID NO:5, as provided in
In some embodiments, the sdABD-EGFR (e.g., sdABD-hαEGFR1) has a sdCDR1 with SEQ ID NO:10, a sdCDR2 with SEQ ID NO:11 and a sdCDR3 with SEQ ID NO:12. In some cases, the sdABD-EGFR has the amino acid sequence of SEQ ID NO:9, as provided in
In some embodiments, the sdABD-EGFR (e.g., sdABD-aEGFR2a) has a sdCDR1 with SEQ ID NO:14, a sdCDR2 with SEQ ID NO:15 and a sdCDR3 with SEQ ID NO:16. In some cases, the sdABD-EGFR has the amino acid sequence of SEQ ID NO:13, as provided in
In some embodiments, the sdABD-EGFR (e.g., sdABD-hαEGFR2d) has a sdCDR1 with SEQ ID NO:18, a sdCDR2 with SEQ ID NO:19 and a sdCDR3 with SEQ ID NO:20. In some cases, the sdABD-EGFR has the amino acid sequence of SEQ ID NO:17, as provided in
As shown in
In some embodiments, the sdABD-EpCAM (e.g., sdABD-EpCAM h13) has a sdCDR1 with SEQ ID NO:62, a sdCDR2 with SEQ ID NO:63, a sdCDR3 with SEQ ID NO:64. In some cases, the sdABD-EpCAM has the amino acid sequence of SEQ ID NO:61, as provided in
In some embodiments, the sdABD-EpCAM (e.g., sdABD-EpCAM h23) has a sdCDR1 with SEQ ID NO:66, a sdCDR2 with SEQ ID NO:67, a sdCDR3 with SEQ ID NO:68. In some cases, the sdABD-EpCAM has the amino acid sequence of SEQ ID NO:65, as provided in
In some embodiments, the sdABD-EpCAM (e.g., sdABD-EpCAM hVIB665) has a sdCDR1 with SEQ ID NO:70, a sdCDR2 with SEQ ID NO:71, a sdCDR3 with SEQ ID NO:72. In some cases, the sdABD-EpCAM has the amino acid sequence of SEQ ID NO:69, as provided in
In some embodiments, the sdABD-EpCAM (e.g., sdABD-EpCAM hVIB666) has a sdCDR1 with SEQ ID NO:74, a sdCDR2 with SEQ ID NO:75, a sdCDR3 with SEQ ID NO:76. In some cases, the sdABD-EpCAM has the amino acid sequence of SEQ ID NO:73, as provided in
In some embodiments, the sdABD-EpCAM (e.g., humanized a EpCAM sdAb) has a sdCDR1 with SEQ ID NO:496, a sdCDR2 with SEQ ID NO:497, a sdCDR3 with SEQ ID NO:498. In some cases, the sdABD-EpCAM has the amino acid sequence of SEQ ID NO:495, as provided in
As shown in
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF7) has a sdCDR1 with SEQ ID NO:34, a sdCDR2 with SEQ ID NO:35, a sdCDR3 with SEQ ID NO:36. In some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:33, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF12) has a sdCDR1 with SEQ ID NO:38, a sdCDR2 with SEQ ID NO:39, a sdCDR3 with SEQ ID NO:40. In some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:37, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF12 (N57Q)) has a sdCDR1 with SEQ ID NO:42, a sdCDR2 with SEQ ID NO:43, a sdCDR3 with SEQ ID NO:44. IN some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:41, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 HF12 (N57E)) has a sdCDR1 with SEQ ID NO:46, a sdCDR2 with SEQ ID NO:47, and a sdCDR3 with SEQ ID NO:48. In some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:45, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF12 (N57D)) has a sdCDR1 with SEQ ID NO:50, a sdCDR2 with SEQ ID NO:51, a sdCDR3 with SEQ ID NO:52. In some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:49, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF12(S59A)) has a sdCDR1 with SEQ ID NO:54, a sdCDR2 with SEQ ID NO:55, a sdCDR3 with SEQ ID NO:56. IN some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:53, as provided as
In one useful embodiment, the sdABD-B7H3 (e.g., sdABD-B7H3 hF12 (S59Y)) has a sdCDR1 with SEQ ID NO:58, a sdCDR2 with SEQ ID NO:59, a sdCDR3 with SEQ ID NO:60. IN some cases, the sdABD-B7H3 has the amino acid sequence of SEQ ID NO:57, as provided as
As shown in
In one useful embodiment, the sdABD-FOLR1 (e.g., sdABD-FOLR1 h77-2) has a sdCDR1 with SEQ ID NO:22, a sdCDR2 with SEQ ID NO:23, a sdCDR3 with SEQ ID NO:24. In some cases, the sdABD-FOLR1 has the amino acid sequence of SEQ ID NO:21, as provided in
In one useful embodiment, the sdABD-FOLR1 (e.g., sdABD-FOLR1 h59.3) has a sdCDR1 with SEQ ID NO:26, a sdCDR2 with SEQ ID NO:27, a sdCDR3 with SEQ ID NO:28. In some cases, the sdABD-FOLR1 has the amino acid sequence of SEQ ID NO:25, as provided in
In one useful embodiment, the sdABD-FOLR1 (e.g., sdABD-FOLR1 h22-4) has a sdCDR1 with SEQ ID NO:30, a sdCDR2 with SEQ ID NO:31, a sdCDR3 with SEQ ID NO:32. In some cases, the sdABD-FOLR1 has the amino acid sequence of SEQ ID NO:29, as provided in
As shown in
In one useful embodiment, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB557) has a sdCDR1 with SEQ ID NO:78, a sdCDR2 with SEQ ID NO:79, a sdCDR3 with SEQ ID NO:80. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:77, as provided in
In some embodiments, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB565) has a sdCDR1 with SEQ ID NO:82, a sdCDR2 with SEQ ID NO:83, a sdCDR3 with SEQ ID NO:84. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:81, as provided in
In some embodiments, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB575) has a sdCDR1 with SEQ ID NO:86, a sdCDR2 with SEQ ID NO:87, a sdCDR3 with SEQ ID NO:88. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:85, as provided in
In some embodiments, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB578) has a sdCDR1 with SEQ ID NO:90, a sdCDR2 with SEQ ID NO:91, a sdCDR3 with SEQ ID NO:92. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:89, as provided in
In some embodiments, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB609) has a sdCDR1 with SEQ ID NO:94, a sdCDR2 with SEQ ID NO:95, a sdCDR3 with SEQ ID NO:96. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:93, as provided in
In some embodiments, the sdABD-Trop2 (e.g., sdABD-Trop2 hVIB619) has a sdCDR1 with SEQ ID NO:98, a sdCDR2 with SEQ ID NO:99, a sdCDR3 with SEQ ID NO:100. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:97, as provided in
As shown in
In some embodiments, the sdABD-CA9 (e.g., sdABD-CA9 hVIB456) has a sdCDR1 with SEQ ID NO:102, a sdCDR2 with SEQ ID NO:103, a sdCDR3 with SEQ ID NO:104. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:101, as provided in
In some embodiments, the sdABD-CA9 (e.g., sdABD-CA9 hVIB476) has a sdCDR1 with SEQ ID NO:106, a sdCDR2 with SEQ ID NO:107, a sdCDR3 with SEQ ID NO:108. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:105, as provided in
In some embodiments, the sdABD-CA9 (e.g., sdABD-CA9 hVIB407) has a sdCDR1 with SEQ ID NO:110, a sdCDR2 with SEQ ID NO:111, a sdCDR3 with SEQ ID NO:112. IN some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:109, as provided in
In some embodiments, the sdABD-CA9 (e.g., sdABD-CA9 hVIB445) has a sdCDR1 with SEQ ID NO:114, a sdCDR2 with SEQ ID NO:115, a sdCDR3 with SEQ ID NO:116. In some cases, the sdABD-Trop2 has the amino acid sequence of SEQ ID NO:113, as provided in
As shown in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 h787) has a sdCDR1 with SEQ ID NO:118, a sdCDR2 with SEQ ID NO:119, a sdCDR3 with SEQ ID NO:120. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:117, as provided in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 h790) has a sdCDR1 with SEQ ID NO:122, a sdCDR2 with SEQ ID NO:123, a sdCDR3 with SEQ ID NO:124. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:121, as provided in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 H804) has a sdCDR1 with SEQ ID NO:126, a sdCDR2 with SEQ ID NO:127, a sdCDR3 with SEQ ID NO:128. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:125, as provided in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 h773) has a sdCDR1 with SEQ ID NO:130, a sdCDR2 with SEQ ID NO:131, a sdCDR3 with SEQ ID NO:132. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:129, as provided in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 h840) has a sdCDR1 with SEQ ID NO:134, a sdCDR2 with SEQ ID NO:135, a sdCDR3 with SEQ ID NO:136. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:133, as provided in
In one useful embodiment, the sdABD-LyPD3 (e.g., sdABD-LyPD3 h885) has a sdCDR1 with SEQ ID NO:138, a sdCDR2 with SEQ ID NO:139, a sdCDR3 with SEQ ID NO:140. In some cases, the sdABD-LyPD3 has the amino acid sequence of SEQ ID NO:137, as provided in
As shown in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1054) has a sdCDR1 with SEQ ID NO:142, a sdCDR2 with SEQ ID NO:143, a sdCDR3 with SEQ ID NO:144. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:141, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1055) has a sdCDR1 with SEQ ID NO:146, a sdCDR2 with SEQ ID NO:147, a sdCDR3 with SEQ ID NO:148. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:145, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1074) has a sdCDR1 with SEQ ID NO:150, a sdCDR2 with SEQ ID NO:151, a sdCDR3 with SEQ ID NO:152. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:149, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1059) has a sdCDR1 with SEQ ID NO:154, a sdCDR2 with SEQ ID NO:155, a sdCDR3 with SEQ ID NO:156. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:153, as provided in
some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1065) has a sdCDR1 with SEQ ID NO:158, a sdCDR2 with SEQ ID NO:159, a sdCDR3 with SEQ ID NO:160. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:157, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1090) has a sdCDR1 with SEQ ID NO:162, a sdCDR2 with SEQ ID NO:163, a sdCDR3 with SEQ ID NO:164. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:161, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1191) has a sdCDR1 with SEQ ID NO:166, a sdCDR2 with SEQ ID NO:167, a sdCDR3 with SEQ ID NO:168. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:165, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1092) has a sdCDR1 with SEQ ID NO:170, a sdCDR2 with SEQ ID NO:171, a sdCDR3 with SEQ ID NO:172. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:169, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1097) has a sdCDR1 with SEQ ID NO:174, a sdCDR2 with SEQ ID NO:175, a sdCDR3 with SEQ ID NO:176. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:173, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1118) has a sdCDR1 with SEQ ID NO:178, a sdCDR2 with SEQ ID NO:179, a sdCDR3 with SEQ ID NO:180. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:177, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1121) has a sdCDR1 with SEQ ID NO:182, a sdCDR2 with SEQ ID NO:183, a sdCDR3 with SEQ ID NO:184. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:181, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1134) has a sdCDR1 with SEQ ID NO:186, a sdCDR2 with SEQ ID NO:187, a sdCDR3 with SEQ ID NO:188. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:185, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1138) has a sdCDR1 with SEQ ID NO:190, a sdCDR2 with SEQ ID NO:191, a sdCDR3 with SEQ ID NO:192. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:189, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1139) has a sdCDR1 with SEQ ID NO:194, a sdCDR2 with SEQ ID NO:195, a sdCDR3 with SEQ ID NO:196. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:193, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1140) has a sdCDR1 with SEQ ID NO:198, a sdCDR2 with SEQ ID NO:199, a sdCDR3 with SEQ ID NO:200. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:197, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1145) has a sdCDR1 with SEQ ID NO:202, a sdCDR2 with SEQ ID NO:203, a sdCDR3 with SEQ ID NO:204. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:201, as provided in
some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1146) has a sdCDR1 with SEQ ID NO:206, a sdCDR2 with SEQ ID NO:207, a sdCDR3 with SEQ ID NO:203. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:205, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1149) has a sdCDR1 with SEQ ID NO:210, a sdCDR2 with SEQ ID NO:211, a sdCDR3 with SEQ ID NO:212. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:209, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1150) has a sdCDR1 with SEQ ID NO:214, a sdCDR2 with SEQ ID NO:215, a sdCDR3 with SEQ ID NO:216. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:213, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1156) has a sdCDR1 with SEQ ID NO:218, a sdCDR2 with SEQ ID NO:219, a sdCDR3 with SEQ ID NO:220. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:217, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1158) has a sdCDR1 with SEQ ID NO:222, a sdCDR2 with SEQ ID NO:223, a sdCDR3 with SEQ ID NO:224. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:221, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1159) has a sdCDR1 with SEQ ID NO:226, a sdCDR2 with SEQ ID NO:227, a sdCDR3 with SEQ ID NO:228. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:225, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1160) has a sdCDR1 with SEQ ID NO:230, a sdCDR2 with SEQ ID NO:231, a sdCDR3 with SEQ ID NO:232. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:229, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1161) has a sdCDR1 with SEQ ID NO:234, a sdCDR2 with SEQ ID NO:235, a sdCDR3 with SEQ ID NO:236. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:233, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1162) has a sdCDR1 with SEQ ID NO:238, a sdCDR2 with SEQ ID NO:239, a sdCDR3 with SEQ ID NO:240. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:237, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1163) has a sdCDR1 with SEQ ID NO:242, a sdCDR2 with SEQ ID NO:243, a sdCDR3 with SEQ ID NO:244. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:241, as provided in
In some embodiments, the sdABD-HER2 (e.g., sdABD-HER2 1058) has a sdCDR1 with SEQ ID NO:150, a sdCDR2 with SEQ ID NO:538, a sdCDR3 with SEQ ID NO:152. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:536, as provided in
In some embodiments, the humanized sdABD-HER2 (e.g., sdABD-HER2 h1058) has a sdCDR1 with SEQ ID NO:150, a sdCDR2 with SEQ ID NO:538, a sdCDR3 with SEQ ID NO:152. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:537, as provided in
In some embodiments, the sdABD-HER2 (e.g., humanized aHER2 sdAb h1130) has a sdCDR1 with SEQ ID NO:500, a sdCDR2 with SEQ ID NO:501, a sdCDR3 with SEQ ID NO:502. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:499, as provided in
In some embodiments, the sdABD-HER2 (e.g., humanized aHER2 sdAb h1156) has a sdCDR1 with SEQ ID NO:504, a sdCDR2 with SEQ ID NO:505, a sdCDR3 with SEQ ID NO:506. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:503, as provided in
In some embodiments, the sdABD-HER2 (e.g., humanized aHER2 sdAb h1159) has a sdCDR1 with SEQ ID NO:508, a sdCDR2 with SEQ ID NO:509, a sdCDR3 with SEQ ID NO:510. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:507, as provided in
In some embodiments, the sdABD-HER2 (e.g., humanized aHER2 sdAb h1162) has a sdCDR1 with SEQ ID NO:512, a sdCDR2 with SEQ ID NO:513, a sdCDR3 with SEQ ID NO:514. In some cases, the sdABD-HER2 has the amino acid sequence of SEQ ID NO:511, as provided in
In some embodiments, the protein prior to cleavage of the protease cleavage domain is less than about 100 kDa. In some embodiments, the protein after cleavage of the protease cleavage domain is about 25 to about 75 kDa. In some embodiments, the protein prior to protease cleavage has a size that is above the renal threshold for first-pass clearance. In some embodiments, the protein prior to protease cleavage has an elimination half-time of at least about 50 hours. In some embodiments, the protein prior to protease cleavage has an elimination half-time of at least about 100 hours. In some embodiments, the protein has increased tissue penetration as compared to an IgG to the same target antigen. In some embodiments, the protein has increased tissue distribution as compared to an IgG to the same target antigen.
The MCE proteins of the invention (again, also referred to herein as “COBRA™” proteins or constructs) optionally include half-life extension domains. Such domains are contemplated to include but are not limited to HSA binding domains, Fc domains, small molecules, and other half-life extension domains known in the art.
Human serum albumin (HSA) (molecular mass ~67 kDa) is the most abundant protein in plasma, present at about 50 mg/ml (600 µM), and has a half-life of around 20 days in humans. HSA serves to maintain plasma pH, contributes to colloidal blood pressure, functions as carrier of many metabolites and fatty acids, and serves as a major drug transport protein in plasma.
Noncovalent association with albumin extends the elimination half-time of short lived proteins. For example, a recombinant fusion of an albumin binding domain to a Fab fragment resulted in a reduced in vivo clearance of 25- and 58-fold and a half-life extension of 26- and 37-fold when administered intravenously to mice and rabbits respectively as compared to the administration of the Fab fragment alone. In another example, when insulin is acylated with fatty acids to promote association with albumin, a protracted effect was observed when injected subcutaneously in rabbits or pigs. Together, these studies demonstrate a linkage between albumin binding and prolonged action.
In many embodiments, the half-life extension domain is a single domain antigen binding domain from a single domain antibody that binds to HSA. This domain is generally referred to herein as “sdABD” to human HSA (sdABD-HSA), or alternatively “sdABD(½)”, to distinguish these binding domains from the sdABDs to TTAs. A particularly useful sdABD(½) is shown in
In some embodiments, the sdABD-HSA (e.g., sdABD-HSA (10GE)) has a sdCDR1 with SEQ ID NO:246, a sdCDR2 with SEQ ID NO:247, a sdCDR3 with SEQ ID NO:248. In some embodiments, the sdABD-HSA has the amino acid sequences of SEQ ID NO:245. In certain embodiments, the sdABD-HSA (e.g., sdABD-HSA with a histidine (His) tag) has a sdCDR1 with SEQ ID NO:250, a sdCDR2 with SEQ ID NO:251, a sdCDR3 with SEQ ID NO:252. In some embodiments, the sdABD-HSA has the amino acid sequences of SEQ ID NO:249.
The half-life extension domain of an antigen binding protein provides for altered pharmacodynamics and pharmacokinetics of the antigen binding protein itself. As above, the half-life extension domain extends the elimination half-time. The half-life extension domain also alters pharmacodynamic properties including alteration of tissue distribution, penetration, and diffusion of the antigen-binding protein. In some embodiments, the half-life extension domain provides for improved tissue (including tumor) targeting, tissue penetration, tissue distribution, diffusion within the tissue, and enhanced efficacy as compared with a protein without a half-life extension binding domain. In one embodiment, therapeutic methods effectively and efficiently utilize a reduced amount of the antigen-binding protein, resulting in reduced side effects, such as reduced non-tumor cell cytotoxicity.
Further, characteristics of the half-life extension domain, for example a HSA binding domain, include the binding affinity of the HSA binding domain for HSA. Affinity of the HSA binding domain can be selected so as to target a specific elimination half-time in a particular polypeptide construct. Thus, in some embodiments, the HSA binding domain has a high binding affinity. In other embodiments, the HSA binding domain has a medium binding affinity. In yet other embodiments, the HSA binding domain has a low or marginal binding affinity. Exemplary binding affinities include KD concentrations at 10 nM or less (high), between 10 nM and 100 nM (medium), and greater than 100 nM (low). As above, binding affinities to HSA are determined by known methods such as Surface Plasmon Resonance (SPR).
The protein compositions of the invention, and particularly the prodrug constructs, include one or more protease cleavage sites, generally resident in cleavable linkers, as outlined herein.
As described herein, the prodrug constructs of the invention include at least one protease cleavage site comprising an amino acid sequence that is cleaved by at least one protease. In some cases, the MCE proteins described herein comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more protease cleavage sites that are cleaved by at least one protease. As is more fully discussed herein, when more than one protease cleavage site is used in a prodrug construction, they can be the same (e.g. multiple sites that are cleaved by a single protease) or different (two or more cleavage sites are cleaved by at least two different proteases). As will be appreciated by those in the art, constructs containing three or more protease cleavage sites can utilize one, two, three, etc.; e.g. some constructs can utilize three sites for two different proteases, etc.
The amino acid sequence of the protease cleavage site will depend on the protease that is targeted. As is known in the art, there are a number of human proteases that are found in the body and can be associated with disease states.
Proteases are known to be secreted by some diseased cells and tissues, for example tumor or cancer cells, creating a microenvironment that is rich in proteases or a protease-rich microenvironment. In some cases, the blood of a subject is rich in proteases. In some cases, cells surrounding the tumor secrete proteases into the tumor microenvironment. Cells surrounding the tumor secreting proteases include but are not limited to the tumor stromal cells, myofibroblasts, blood cells, mast cells, B cells, NK cells, regulatory T cells, macrophages, cytotoxic T lymphocytes, dendritic cells, mesenchymal stem cells, polymorphonuclear cells, and other cells. In some cases, proteases are present in the blood of a subject, for example proteases that target amino acid sequences found in microbial peptides. This feature allows for targeted therapeutics such as antigen-binding proteins to have additional specificity because T cells will not be bound by the antigen binding protein except in the protease rich microenvironment of the targeted cells or tissue.
Proteases are proteins that cleave proteins, in some cases, in a sequence-specific manner. Proteases include but are not limited to serine proteases, cysteine proteases, aspartate proteases, threonine proteases, glutamic acid proteases, metalloproteases, asparagine peptide lyases, serum proteases, cathepsins (e.g. cathepsin B, cathepsin C, cathepsin D, cathepsin E, cathepsin K, cathepsin L, cathepsinS, etc.), kallikreins, hK1, hK10, hK15, KLK7, granzymeB, plasmin, collagenase, Type IV collagenase, stromelysin, factor XA, chymotrypsin-like protease, trypsin-like protease, elastase-like protease, subtilisin-like protease, actinidain, bromelain, calpain, caspases (e.g. caspase-3), Mir1-CP, papain, HIV-1 protease, HSV protease, CMV protease, chymosin, renin, pepsin, matriptase, legumain, plasmepsin, nepenthesin, metalloexopeptidases, metalloendopeptidases, matrix metalloproteases (MMP), MMP1, MMP2, MMP3, MMP8, MMP9, MMP13, MMP11, MMP14, meprin, urokinase plasminogen activator (uPA), enterokinase, prostate-specific antigen (PSA, hK3), interleukin-1β converting enzyme, thrombin, FAP (FAP-α), dipeptidyl peptidase, and dipeptidyl peptidase IV (DPPIV/CD26).
Some suitable proteases and protease cleavage sequences are shown in
As is discussed herein, the different domains of the invention are generally linked together using amino acid linkers, which can confer functionality as well, including flexibility or inflexibility (e.g. steric constraint) as well as the ability to be cleaved using an in situ protease. These linkers can be classified in a number of ways.
The invention provides “domain linkers”, which are used to join two or more domains (e.g. a VH and a VL, a target tumor antigen binding domain (TTABD, sometimes also referred to herein as “αTTA” (for “anti-TTA”) to a VH or VL, a half life extension domain to another component, etc.). Domain linkers can be non-cleavable (“NCL”), cleavable (“CL”), constrained and cleavable (“CCL”) and constrained and non-cleavable “(CNCL”), for example.
In some embodiments, the domain linker is non-cleavable. Generally, these can be one of two types: non-cleavable and flexible, allowing for the components “upstream” and “downstream” of the linker in the constructs to intramolecularly self-assemble in certain ways; or non-cleavable and constrained, where the two components separated by the linker are not able to intramolecularly self-assemble. It should be noted, however, that in the latter case, while the two component domains that are separated by the non-cleavable constrained linker do not intramolecularly self-assemble, other intramolecular components will self-assemble to form the pseudo Fv domains.
In this embodiment, the linker is used to join domains to preserve the functionality of the domains, generally through longer, flexible domains that are not cleaved by in situ proteases in a patient. Examples of internal, non-cleavable linkers suitable for linking the domains in the polypeptides of the invention include but are not limited to (GS)n, (GGS)n, (GGGS)n [SEQ ID NO:518], (GGSG)n [SEQ ID NO:519], (GGSGG)n [SEQ ID NO:520], or (GGGGS)n [SEQ ID NO:521], wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments the length of the linker can be about 15 amino acids.
In some cases, the linkers do not contain a cleavage site and are also too short to allow the protein domains separated by the linker to intramolecularly self-assemble, and are “constrained non-cleavable linkers” or “CNCLs”. For example, in Pro186, an active VH and an active VL are separated by 8 amino acids (an “8-mer” or “8mer”) that does not allow the VH and VL to self-assemble into an active antigen binding domain. In some embodiments, the linker is still flexible; for example, (GGGS)n where n = 2. In other embodiments, although generally less preferred, more rigid linkers can be used, such as those that include proline or bulky amino acids.
All of the prodrug constructs herein include at least one cleavable linker. Thus, in one embodiment, the domain linker is cleavable (CL), sometimes referred to herein as a “protease cleavage domain” (“PCD”). In this embodiment, the CL contains a protease cleavage site, as outlined herein and as depicted in
Of particular interest in the present invention are MMP9 cleavable linkers and meprin cleavable linkers, particularly MMP9 constrained cleavable linkers and meprin constrained cleavable linkers.
The present invention provides a number of different formats for the prodrug polypeptides of the invention. The present invention provides constrained Fv domains and constrained pseudo Fv domains. Additionally, the present invention provides multivalent conditionally effective (“MCE”) proteins which contain two Fv domains but are non-isomerizing constructs. As outlined herein, these can be non-isomerizing cleavable formats or non-isomerizing non-cleavable formats, although every construct contains at least one protease cleavage domain.
Importantly, while both of these domains (Fv domains and pseudo Fv domains) are referred to herein as “constrained”, meaning that as discussed above and shown in
Those of skill in the art will appreciate that for Formats 1, 2 and 4, there are four possibilities for the N- to C-terminal order of the constrained and pseudo Fv domains of the invention (not showing the linkers): aVH-aVL and iVL-iVH, aVH-aVL and iVH-iVL, aVL-aVH and iVL-iVH, aVL-aVH and iVH-iVL. All four have been tested and all four have activity, although the first order, aVH-aVL and iVL-iVH, shows better expression than the other three. Thus while the description herein is generally shown in this aVH-aVL and iVL-iVH format, all disclosure herein includes the other orders for these domains as well.
Note that generally, the N to C-terminal order for the full length constructs of the invention is based on the aVH-aVL and iVL-iVH orientation.
Additionally, it is known in the art that there can be immunogenicity in humans originating from the C-terminal sequences of certain ABDs. Accordingly, in general, particularly when the C-terminus of the constructs terminates in a sdABD (for example, the sdABD-HSA domains of many of the constructs, a histidine tag (either His6 or His10) can be used. Many or most of the sequences herein were generated using His6 C-terminal tags for purification reasons, but these sequences can also be used to reduce immunogenicity in humans, as is shown by Holland et al., DOI 10.1007/s10875-013-9915-0 and WO2013/024059.
The present invention provides constrained Fv domains, that comprise an active VH and an active VL domain that are covalently attached using a constrained linker (which, as outlined herein, can be cleavable (Format 1) or non-cleavable (Formats 2 and 4)). The constrained linker prevents intramolecular association between the aVH and aVL in the absence of cleavage. Thus, a constrained Fv domain general comprises a set of six CDRs contained within variable domains, wherein the vhCDR1, vhCDR2 and vhCDR3 of the VH bind human CD3 and the vlCDR1, vCDR2 and vlCDR3 of the VL bind human CD3, but in the prodrug format (e.g. uncleaved), the VH and VL are unable to sterically associate to form an active binding domain, preferring instead to pair intramolecularly with the pseudo Fv.
The constrained Fv domains can comprise active VH and active VL (aVH and aVL) or inactive VH and VL (iVH and iVL, in which case it is a constrained pseudo Fv domain) or combinations thereof as described herein.
As will be appreciated by those in the art, the order of the VH and VL in a constrained Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
As outlined herein, for Format 1 constructs, the constrained Fv domains can comprise a VH and a VL linked using a cleavable linker, in cases such as those shown in
As outlined herein, for Format 2 constructs, the constrained Fv domains can comprise a VH and a VL linked using a non-cleavable linker. In this embodiment, the constrained Fv domain has the structure (N- to C-terminus) vhFR1-vhCDR1-vhFR2-vhCDR2-vhFR3-vhCDR3-vhFR4-CNCL-vlFR1-vlCDR1-vlFR2-vlCDR2-vlFR3-vlCDR3-vlFR4. In general, the constrained Fv domain contains active VH and VL domains (e.g. able to bind CD3 when associated) and thus has the structure (N- to C-terminus) vhFR1-avhCDR1-vhFR2-avhCDR2-vhFR3-avhCDR3-vhFR4-CNCL-vlFR1-avlCDR1-vlFR2-avlCDR2-vlFR3-avlCDR3-vlFR4.
Of particular use in the present invention are constrained non-cleavable Fv domains having an aVH having SEQ ID NO:270, an aVL having SEQ ID NO:254, and a domain linker having SEQ ID NO:287.
The present invention provides constrained pseudo Fv domains, comprising inactive or pseudo iVH and iVL domains that are covalently attached using a constrained linker (which, as outlined herein, can be cleavable or non-cleavable). The constrained linker prevents intramolecular association between the iVH and iVL in the absence of cleavage. Thus, a constrained pseudo Fv domain general comprises an iVH and an iVL with framework regions that allow association (when in a non-constrained format) of the iVH and iVL, although the resulting pseudo Fv domain does not bind to a human protein. iVH domains can assemble with aVL domains, and iVL domains can assemble with aVH domains, although the resulting structures do not bind to CD3.
The constrained pseudo Fv domains comprise inactive VH and VL (iVH and iVL).
As will be appreciated by those in the art, the order of the VH and VL in a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
As outlined herein, the constrained pseudo Fv domains can comprise a iVH and an iVL linked using a non-cleavable linker, as shown in Formats 1, 2 and 4, or with cleavable linkers, as shown in Format 3.
In general, the constrained Fv domain contains inert VH and VL domains (e.g. able to bind CD3 when associated) and thus has the structure (N- to C-terminus) vhFR1-ivlCDR1-vhFR2-ivlCDR2-vhFR3-ivlCDR3-vhFR4-CNCL-vlFR1-ivhCDR1-vlFR2-ivhCDR2-vlFR3-ivhCDR3-vlFR4.
Of particular use in the present invention are constrained non-cleavable pseudo Fv domains having (i) an iVH having SEQ ID NO:274 (αCD3 VHi), SEQ ID NO:278 (αCD3 VHi2) or SEQ ID NO:282 (αCD3 VHiGL4), (ii) an iVL having SEQ ID NO:258 (αCD3 VLi), SEQ ID NO:262 (αCD3 VLi2) or SEQ ID NO:266 (αCD3 VLiGL), and (iii) a domain linker having SEQ ID NO:287. In some embodiments, a constrained non-cleavable pseudo Fv domain comprises (i) an iVH having an amino acid sequence of SEQ ID NO:274 (αCD3 VHi), (ii) an iVL having an amino acid sequence of SEQ ID NO:258 (αCD3 VLi), and (iii) a domain linker having an amino acid sequence of SEQ ID NO:287. In some embodiments, a constrained non-cleavable pseudo Fv domain comprises (i) an iVH having an amino acid sequence of SEQ ID NO:278 (αCD3 VHi2), (ii) an iVL having an amino acid sequence of SEQ ID NO:262 (αCD3 VLi2), and (iii) a domain linker having an amino acid sequence of SEQ ID NO:287. In some embodiments, a constrained non-cleavable pseudo Fv domain comprises (i) an iVH having an amino acid sequence of SEQ ID NO:282 (αCD3 VHi2GL4), (ii) an iVL having an amino acid sequence of SEQ ID NO:266 (αCD3 VLi2GL), and (iii) a domain linker having an amino acid sequence of SEQ ID NO:287
As discussed herein, the pro-drug constructs of the invention can take on a number of different formats, including cleavable formats with dual TTA binding domains, non-cleavable formats with dual TTA binding domains (either of which can have the same TTA binding domains or different binding domains), and non-cleavable formats with a single targeting domain.
As shown in
As will be appreciated by those in the art, the order of the VH and VL in either a constrained Fv domain or a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
The invention provides prodrug proteins, comprising, from N- to C-terminal: (sdABD-TTA1)-domain linker-constrained Fv domain-domain linker-(sdABD-TTA2)-cleavable linker-constrained pseudo Fv domain-domain linker-(sdABD-HSA).
As will be appreciated by those in the art, the order of the VH and VL in either a constrained Fv domain or a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA).
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVH-CNCL-iVL-domain linker-(sdABD-HSA).
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVL-CNCL-aVH-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA).
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVL-CNCL-aVH-domain linker-(sdABD-TTA2)-CL-iVH-CNCL-iVL-domain linker-(sdABD-HSA).
In some embodiments, the prodrug protein described herein is provided in the figures including
In some embodiments, a COBRA construct is generated using the anti-HER2 VIB1058 sdABD (SEQ ID NO:536; e.g., an aHER2 1058 COBRA) or the hVIB1058 sdABD (SEQ ID NO:537; e.g., a humanized aHER2 1058 COBRA). In some such embodiments, the COBRA includes two copies of the VIB 1058 sdABD or hVIB1058 sdABD, e.g., a single targeting format 2 construct / “mono-specific COBRA.” In some such embodiments, the COBRA includes one copy of the VIB1058 sdABD or hVIB 1058 sdABD, e.g., a dual targeting format 2 Construct / “heteroCOBRA.”
In some embodiments, both of the αTTA domains bind to the same tumor target. Accordingly, in some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 and sdABD-TTA2 bind the same target antigen. In some embodiments, the sdABD-TTA1 and the sdABD-TTA2 bind the same target antigen but at different locations. In some embodiments, the sdABD-TTA1 and the sdABD-TTA2 bind the same target antigen but at the same location. In some embodiments, the sdABD-TTA1 and the sdABD-TTA2 have the same amino acid sequence. Any sequence of the sdABDs described herein can be the sequence of the sdABD-TTA1, the sdABD-TTA2, or both. In some embodiments, the sdCDR1, sdCDR2 and sdCDR3 of sdABD-TTA1 are the same as the the sdCDR1, sdCDR2 and sdCDR3 of sdABD-TTA2, respectively.
In some embodiments, exemplary mono-specific COBRAs bind to a tumor target selected from the group consisting of B7H3, CA9, EGFR, EpCAM, HER2, LyPD3 and Trop2. In some embodiments, a mono-specific COBRA that bind to B7H3 (e.g., human B7H3) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to CA9 (e.g., human CA9) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to EGFR (e.g., human EGFR) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to EpCAM (e.g., human EpCAM) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to FOLR1 (e.g., human FOLR1) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to HER2 (e.g., human HER2) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to LyPD3 (e.g., human LyPD3) includes any of the fusion proteins of
In some embodiments, a mono-specific COBRA that bind to Trop2 (e.g., human Trop2) includes any of the fusion proteins of
In some embodiments, each of the αTTA domains bind to a different tumor target. Accordingly, in some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In Format 2, preferred dual targeting constructs (sometimes referred to herein as “hetero-COBRAs”) include combinations that target EGFR and EpCAM, EGFR and Trop2, EGFR and FOLR1, EGFR and B7H3, EGFR and LyPD3, EGFR and HER2, EpCAM and FOLR1, EpCAM and B7H3, EpCAM and Trop2, EpCAM and LyPD3, EpCAM and HER2, FOLR1 and B7H3, FOLR1 and HER2, FOLR1 and Trop2, FOLR1 and LyPD3, B7H3 and HER2, B7H3 and Trop2, B7H3 and LyPD3, HER2 and Trop2, HER2 and LyPD3, and Trop2 and LyPD3. These sometimes are discussed herein as “EGFR X EpCAM”, etc., constructs.
In some embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 and sdABD-TTA2 bind different target antigens.
In some embodiments, the sdABD-TTA1 is a sdABD-B7H3 and the sdABD-TTA2 is selected from the group consisting of a sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-CA9 and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-EGFR and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-EpCAM and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-HER2 and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-LyPD3, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-LyPD3 and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, and sdABD-Trop2. In some embodiments, the sdABD-TTA1 is a sdABD-Trop2 and the sdABD-TTA2 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, and sdABD-LyPD3. Any sequence of a sdABD-TTA described herein such as those of a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-HER2, a sdABD-LyPD3 and a sdABD-Trop2 can be used in a dual targeting format 2 construct or hetero-COBRA.
In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-B7H3. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-CA9. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EpCAM, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-EGFR. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-HER2, sdABD-LyPD3, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-EpCAM. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-LyPD3, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-HER2. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, and sdABD-Trop2, and the sdABD-TTA2 is a sdABD-LyPD3. In many embodiments, the sdABD-TTA1 is selected from the group consisting of a sdABD-B7H3, sdABD-CA9, sdABD-EGFR, sdABD-EpCAM, sdABD-HER2, and sdABD-LyPD3, and the sdABD-TTA2 is a sdABD-Trop2. Any sequence of a sdABD-TTA described herein such as those of a sdABD-B7H3, a sdABD-CA9, a sdABD-EGFR, a sdABD-EpCAM, a sdABD-HER2, a sdABD-LyPD3 and a sdABD-Trop2 can be used in such dual targeting format 2 constructs or hetero-COBRAs.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the EpCAM sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or the EpCAM sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the FOLR1 sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or the FOLR1 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the B7H3 sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or the B7H3 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the Trop2 sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the Trop2 sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the HER2 sdABD is N-terminal to the EGFR sdABD in the constructs of the invention or C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the EpCAM sdABD is N-terminal to the FOLR1 sdABD in the constructs of the invention or the EpCAM sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the B7H3 sdABD is N-terminal to the EpCAM sdABD in the constructs of the invention or the B7H3 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” which means that either the Trop2 sdABD is N-terminal to the EpCAM sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” which means that either the LyPD3 sdABD is N-terminal to the EpCAM sdABD in the constructs of the invention or C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “EO” is “either orientation” which means that either the LyPD3 sdABD is N-terminal to the EpCAM sdABD in the constructs of the invention or C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the B7H3 sdABD is N-terminal to the FOLR1 sdABD in the constructs of the invention or C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the HER2 sdABD is N-terminal to the FOLR1 sdABD in the constructs of the invention or the HER2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the Trop2 sdABD is N-terminal to the FOLR1 sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the LyPD3 sdABD is N-terminal to the FOLR1 sdABD in the constructs of the invention or the LyPD3 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the HER2 sdABD is N-terminal to the B7H3 sdABD in the constructs of the invention or the HER2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the Trop2 sdABD is N-terminal to the B7H3 sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the LyPD3 sdABD is N-terminal to the B7H3 sdABD in the constructs of the invention or the LyPD3 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the HER2 sdABD is N-terminal to the Trop2 sdABD in the constructs of the invention or the HER2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the HER2 sdABD is N-terminal to the Trop2 sdABD in the constructs of the invention or C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In some embodiments, the aVH, aVL, iVH, iVL have the sequences shown in
In this case, “either orientation” means that either the Trop2 sdABD is N-terminal to the LyPD3 sdABD in the constructs of the invention or the Trop2 sdABD is C-terminal to it.
In some embodiments, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In Format 2, a preferred domain linker is SEQ ID NO:287 (which also serves as a preferred constrained non cleavable linker).
The invention provides non-isomerizing cleavable formats of the “format 1” type in
All constructs in Format 1 (as well as the other formats) also have a cleavable linker (CL) that is cleaved by a human tumor protease.
The invention provides prodrug proteins, comprising, from N- to C-terminal, (sdABD-TTA1)-domain linker-constrained Fv domain-domain linker-(sdABD-TTA2)-CL-constrained pseudo Fv domain-domain linker-(sdABD-HSA).
As will be appreciated by those in the art, the order of the VH and VL in either a constrained Fv domain or a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CCL-aVL-domain linker-(sdABD-TTA2)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA).
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVH-CCL-aVL-domain linker-(sdABD-TTA2)-CL-iVH-CCL-iVL-domain linker-sdABD-HSA.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVL-CCL-aVH-domain linker-(sdABD-TTA2)-CL-iVL-CCL-iVH-domain linker-(sdABD-HSA).
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA1)-domain linker-aVL-CCL-aVH-domain linker-(sdABD-TTA2)-CL-iVH-CCL-iVL-domain linker-(sdABD-HSA).
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-NCL-sdABD(½). In this embodiment, the aVH, aVL, iVH and iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the prodrug construct comprises sdABD(TTA1)-domain linker-aVH-CCL-aVL-domain linker-sdABD(TTA2)-CL-iVL-CNCL-iVH-domain linker-sdABD(½). In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In Format 1, a preferred domain linker is SEQ ID NO:287 (which also serves as a preferred constrained non cleavable linker).
As is shown in
As will be appreciated by those in the art, the order of the VH and VL in either a constrained Fv domain or a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
The invention provides prodrug proteins, comprising, from N- to C-terminal: (sdABD-TTA)-domain linker-constrained Fv domain-cleavable linker-(sdABD-HSA)-constrained pseudo Fv domain. (Note that for all constructs for this format, the sdABD-HSA does not generally have a His6 tag, although it can be included).
As will be appreciated by those in the art, the order of the VH and VL in either a constrained Fv domain or a constrained pseudo Fv domain can be either (N- to C-terminal) VH-linker-VL or VL-linker-VH.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA)-domain linker-aVH-CNCL-aVL-CL-(sdABD-HSA)-domain linker-iVL-CNCL-iVH.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA)-domain linker-aVH-CNCL-aVL-CL-(sdABD-HSA)-domain linker-iVH-CNCL-iVL.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA)-domain linker-aVL-CNCL-aVH-CL-(sdABD-HSA)-domain linker-iVH-CNCL-iVL.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA)-domain linker-aVL-CNCL-aVH-CL-(sdABD-HSA)-domain linker-iVL-CNCL-iVH.
Thus, in one embodiment, the prodrug protein comprises, from N- to C-terminal: (sdABD-TTA)-domain linker-aVH-CNCL-aVL-CL-(sdABD-HSA)-domain linker-iVL-CNCL-iVH. In this embodiment, the aVH, aVL, iVH, iVL have the sequences shown in
In some embodiments, the compositions of the invention comprise two different molecules, sometimes referred to as “hemi-COBRAs™”, or “hemi-constructs”, that in the absence of cleavage, intramolecularly associate to form pseudo-Fvs. In the presence of the protease, the cleavage sites are cleaved, releasing the inert variable domains, and the protein pair then forms an active antigen binding domain to CD3, as generally depicted in
What is important in the design of the hemi-constructs is that the active variable domain and the sdABD-TTA remain together after cleavage, such that the two cleaved portions are held together by the tumor antigen receptor on the tumor surface and then can form an active anti-CD3 binding domain.
There are two different general Format 3 constructs, those wherein each member of the pair has a single sdABD-TTA (
In some embodiments, the first hemi-COBRA™ has, from N- to C-terminal, sdABD(TTA1)-domain linker-aVH-CL-iVL-domain linker- sdABD(½) and the second has sdABD(½)-domain linker-iVH-CL-aVL-domain linker-sdABD(TTA2). In this embodiment, the aVH, aVL, iVH, iVL and sdABD(½) have the sequences shown in
In some embodiments, the paired pro-drug constructs can have two sdABD-TTA binding domains per construct, as is shown in
The two sdABD-TTAs on each member of the pair are different, but generally both members (hemi-COBRAs™) have the same two sdABD-TTAs, e.g. both have EGFR and FOLR1 or EGFR and B7H3, etc.
The two sdABD-TTAs are in some embodiments selected from the ones shown in
The pro-drug compositions of the invention are made as will generally be appreciated by those in the art and outlined below.
The invention provides nucleic acid compositions that encode the pro-drug compositions of the invention. As will be appreciated by those in the art, the nucleic acid compositions will depend on the format of the pro-drug polypeptide(s). Thus, for example, when the format requires two amino acid sequences, such as the “format 3” constructs, two nucleic acid sequences can be incorporated into one or more expression vectors for expression. Similarly, prodrug constructs that are a single polypeptide (formats 1, 2 and 4), need a single nucleic acid in a single expression vector for production.
As is known in the art, the nucleic acids encoding the components of the invention can be incorporated into expression vectors as is known in the art, and depending on the host cells used to produce the prodrug compositions of the invention. Generally the nucleic acids are operably linked to any number of regulatory elements (promoters, origin of replication, selectable markers, ribosomal binding sites, inducers, etc.). The expression vectors can be extra-chromosomal or integrating vectors.
The nucleic acids and/or expression vectors of the invention are then transformed into any number of different types of host cells as is well known in the art, including mammalian, bacterial, yeast, insect and/or fungal cells, with mammalian cells (e.g. CHO cells, 293 cells), finding use in many embodiments.
The prodrug compositions of the invention are made by culturing host cells comprising the expression vector(s) as is well known in the art. Once produced, traditional antibody purification steps are done, including an protein A affinity chromatography step and/or an ion exchange chromatography step.
Formulations of the pro-drug compositions used in accordance with the present invention are prepared for storage by mixing the pro-drugs (single proteins in the case of formats 1, 2 and 4 and two proteins in the case of format 3) having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (as generally outlined in Remington’s Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions.
The pro-drug compositions of the invention are administered to a subject, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time.
The pro-drug compositions of the invention are useful in the treatment of cancer. Provided herein are methods of treating cancer in a patient comprising any of the pro-drug compositions described. Described herein is a pro-drug composition for use as a medicament. Provided is a pharmaceutical composition for treating cancer comprising any of the pro-drug compositions described. Provided is a pharmaceutical composition comprising any of the pro-drug compositions described for treating cancer in a patient in need thereof. Provided is a pro-drug composition as described for the treatment or for the use in a method for treating cancer. Provided is a pro-drug composition described herein for treating cancer in a patient in need thereof. Provided is the use of a pro-drug composition in the manufacture of a medicament for the treatment of cancer.
The present invention provides a number of different protein compositions for the treatment of cancer. Accordingly, in one aspect, the invention provides “Format 2” proteins comprising, from N- to C-terminal: a first single domain antigen binding domain (sdABD) that binds to a human tumor target antigen (TTA) (sdABD-TTA); b) a domain linker; c) a constrained Fv domain comprising: i) a variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; ii) a constrained non-cleavable linker (CNCL); and iii) a variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; d) a second domain linker; e) a second sdABD-TTA; f) a cleavable linker (CL); g) a constrained pseudo Fv domain comprising: i) a pseudo light variable domain; ii) a constrained non-cleavable linker (CNCL); and iii) a pseudo heavy variable domain; h) a third domain linker; and i) a third sdABD that binds to human serum albumin; wherein the variable heavy domain and the variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; the variable heavy domain and the pseudo variable light domain intramolecularly associate to form an inactive Fv; and the variable light domain and the pseudo variable heavy domain intramolecularly associate to form an inactive Fv. In some embodiments, the human tumor target antigen is B7H3.
In a further aspect, the invention provides proteins comprising, from N- to C-terminal: a first single domain antigen binding domain (sdABD) that binds to a human tumor target antigen (TTA) (sdABD-TTA) comprising sdFR1-sdCDR1-sdFR2-sdCDR2-sdFR3-sdCDR3-sdFR4; b) a first domain linker; c) a constrained Fv domain comprising: i) a variable heavy domain comprising vhFR1-vhCDR1-vhFR2-vhCDR2-vhFR3-vhCDR3-vhFR4; ii) a constrained non-cleavable linker (CNCL); and iii) a variable light domain comprising vlFR1-vlCDR1-vlFR2-vlCDR2-vlFR3-vlCDR3-vlFR4; d) a second domain linker; e) a second sdABD-TTA; f) a cleavable linker (CL); g) a constrained pseudo Fv domain comprising: i) a pseudo light variable domain comprising sdFR1-sdCDR1-sdFR2-sdCDR2-sdFR3-sdCDR3-sdFR4; ii) a constrained non-cleavable linker (CNCL); and iii) a pseudo heavy variable domain comprising vlFR1-vlCDR1-vlFR2-vlCDR2-vlFR3-vlCDR3-vlFR4; h) a third domain linker; and i) a third sdABD that binds to human serum albumin comprising sdFR1-sdCDR1-sdFR2-sdCDR2-sdFR3-sdCDR3-sdFR4; wherein the variable heavy domain and the variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; the variable heavy domain and the pseudo variable light domain intramolecularly associate to form an inactive Fv; and the variable light domain and the pseudo variable heavy domain intramolecularly associate to form an inactive Fv. In some embodiments, the human tumor target antigen is B7H3.
In some embodiments of Format 2 proteins, the variable heavy domain is N-terminal to the variable light domain and the pseudo light variable domain is N-terminal to the pseudo variable heavy domain. In some embodiments, the variable heavy domain is N-terminal to the variable light domain and the pseudo variable light domain is C-terminal to the pseudo variable heavy domain. In some embodiments, the variable heavy domain is C-terminal to the variable light domain and the pseudo variable light domain is N-terminal to the pseudo variable heavy domain. In some embodiments, the variable heavy domain is C-terminal to the variable light domain and the pseudo variable light domain is C-terminal to the pseudo variable heavy domain.
In some embodiments of Format 2 proteins, the first sdABDTTA and the second sdABDTTA are the same. In some embodiments, the first sdABDTTA and the second sdABDTTA are different. In these embodiments, the sdABD-TTAs are selected from those depicted in
In some embodiments of Format 2 proteins, the pseudo heavy variable domain of the constrained pseudo Fv domain is selected from the group of SEQ ID NO:146 (VHi), SEQ ID NO:150 (VHi2) and SEQ ID NO:154 (VHiGL4), as shown in
In a further aspect, the invention provides “Format 1” proteins comprising, from N- to C-terminal: a) a first sdABD-TTA; b) a first domain linker; c) a constrained Fv domain comprising: i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; ii) a constrained cleavable linker (CCL); and iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; d) a second domain linker; e) a second sdABD-TTA; f) a cleavable linker (CL); g) a constrained pseudo Fv domain comprising: i) a first pseudo light variable domain; ii) a constrained non-cleavable linker (CNCL); and iii) a first pseudo heavy variable domain; h) a third domain linker; and i) a third sdABD that binds to human serum albumin; wherein the first variable heavy domain and the first variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; wherein the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and wherein the first variable light domain and the first pseudo variable heavy domain intramolecularly associate to form an inactive Fv. In an additional aspect, the invention provides “Format 4” proteins comprising, from N- to C-terminal: a) a single domain antigen binding domain (sdABD) that binds to a human tumor target antigen (TTA) (sdABD-TTA); b) a first domain linker; c) a constrained Fv domain comprising: i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; ii) a constrained non-cleavable linker (CNCL); and iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; d) a cleavable linker (CL); e) a second sdABD that binds to human serum albumin; f) a domain linker; g) a constrained pseudo Fv domain comprising: i) a first pseudo light variable domain; ii) a constrained non-cleavable linker (CNCL); and iii) a first pseudo heavy variable domain; wherein the first variable heavy domain and the first variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; wherein the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and wherein the first variable light domain and the first pseudo variable heavy domain intramolecularly associate to form an inactive Fv.
In a further aspect to the Format 1, Format 2 and Format 4 proteins listed above, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo light variable domain is N-terminal to the pseudo variable heavy domain.
In a further aspect to the Format 1, Format 2 and Format 4 proteins listed above, the first variable heavy domain is N-terminal to the first variable light domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In a further aspect to the Format 1, Format 2 and Format 4 proteins listed above, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo light variable domain is N-terminal to the pseudo variable heavy domain.
In a further aspect to the Format 1, Format 2 and Format 4 proteins listed above, the first variable light domain is N-terminal to the first variable heavy domain and the pseudo variable heavy domain is N-terminal to the pseudo variable light domain.
In an additional aspect, the invention provides Format 1 and 2 proteins wherein the first and second TTA are the same. In a further aspect, the invention provides Format 1 and 2 proteins wherein the first and second TTA are different.
In an additional aspect, the invention provides Format 1, 2 and 4 proteins wherein the first and second TTA are selected from EGFR, EpCAM, FOLR1, Trop2, ca9 and B7H3. These sequences can be selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13; SEQ ID NO:17; SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:57, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73,77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO: 105, SEQ ID NO: 109 and SEQ ID NO:113.
In a further aspect, the invention provides Format 1, 2 and 4 proteins wherein the half-life extension domain has SEQ ID NO: 117 (aHSA (10GE)) and SEQ ID NO: 121 (aHSA with His tag).
In an additional aspect, the invention provides Format 1, 2 and 4 proteins wherein the cleavable linker is cleaved by a human protease selected from the group consisting of MMP2, MMP9, Meprin A, Meprin B, Cathepsin S, Cathepsin K, Cathespin L, GranzymeB, uPA, Kallekriein7, matriptase and thrombin, or others as depicted in
In a further aspect, the invention provides a protein selected from the group consisting of Pro186, Pro225, Pro226, Pro233, Pro262, Pro311, Pro312, Pro313,Pro356, Pro359, Pro364, Pro388, Pro448, Pro449, Pro450, Pro451, Pro495, Pro246, Pro254, Pro255, Pro256, Pro420, Pro421, Pro432, Pro479, Pro480, Pro187, Pro221, Pro222, Pro223, Pro224, Pro393, Pro394, Pro395, Pro396, Pro429, Pro430, Pro431, Pro601, Pro602, V3 and V4, Pro664, Pro665, Pro667, Pro694, Pro695, Pro565, Pro566, Pro567, Pro727, Pro728, Pro729, Pro730, Pro731, Pro676, Pro677, Pro678, Pro679, Pro808, Pro819, Pro621, Pro622, Pro640, Pro641, Pro642, Pro643, Pro744, Pro746, Pro638, Pro639, Pro396, Pro476, Pro706, Pro709, Pro470, Pro471, Pro551, Pro552, Pro623, Pro624, Pro698, Pro655, Pro656, Pro657, Pro658, Pro516, Pro517, Pro518 and Pro519.
In an additional aspect, the invention provides nucleic acids encoding a Format 1, Format 2 or Format 4 protein as described herein, as well as expression vectors and host cells comprising the nucleic acids encoding the protein.
In a further aspect, the invention provides methods of making the proteins of the invention and methods of treating patients in need thereof.
In an additional aspect, the invention provides compositions comprising “Format 3A” pairs of pro-drug proteins, comprising: a) a first protein comprising, from N- to C-terminal: i) a first sdABD-TTA; ii) a first domain linker; iii) a pseudo Fv domain comprising, from N- to C-terminal: 1) a variable heavy chain comprising a vhCDR1, vhCDR2 and vhCDR3; 2) a cleavable linker; and 3) a first pseudo variable light domain comprising iVLCDR1, iVLCDR2 and iVLCDR3; iv) a second domain linker; v) a sdABD-HSA; a) a second protein comprising, from N- to C-terminal: i) a third sdABD that binds to a human tumor target antigen; ii) a third domain linker; iii) a pseudo Fv domain comprising, from N- to C-terminal: 1) a variable light chain comprising a VLCDR1, VLCDR2 and VLCDR3; 2) a cleavable linker; and 3) a first pseudo variable heavy domain comprising iVHCDR1, iVHCDR2 and iVHCDR3; iv) a fourth domain linker; v) a sdABD-HSA; wherein the first variable heavy domain and the first variable light domain are capable of binding human CD3 when associated; wherein the first variable heavy domain and the first pseudo variable light domain intermolecularly associate to form an inactive Fv; wherein the first variable light domain and the first pseudo variable heavy domain intermolecularly associate to form an inactive Fv; and wherein the first and third sdABD are selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13; SEQ ID NO:17; SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:57, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73,77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO: 105, SEQ ID NO: 109 and SEQ ID NO:113.
In a further aspect, the invention provides compositions comprising “Format 3B” pairs of pro-drug proteins, comprising a) a first protein comprising, from N- to C-terminal: i) a first sdABD-TTA; ii) a first domain linker; iii) a second sdABD-TTA; iv) a second domain linker; iii) a pseudo Fv domain comprising, from N- to C-terminal: 1) a variable heavy chain comprising a vhCDR1, vhCDR2 and vhCDR3; 2) a cleavable linker; and 3) a first pseudo variable light domain comprising iVLCDR1, iVLCDR2 and iVLCDR3; iv) a third domain linker; and v) a sdABD-HSA; a) a first second protein comprising, from N- to C-terminal: i) a third sdABD-TTA; ii) a fourth domain linker; iii) a fourth sdABD-TTA; iv) a fifth domain linker; iii) a pseudo Fv domain comprising, from N- to C-terminal: 1) a variable light chain comprising a VLCDR1, VLCDR2 and VLCDR3; 2) a cleavable linker; and 3) a first pseudo variable heavy domain comprising iVHCDR1, iVHCDR2 and iVHCDR3; iv) a sixth domain linker; v) a sdABD-HSA; wherein the first variable heavy domain and the first variable light domain are capable of binding human CD3 when associated; wherein the first variable heavy domain and the first pseudo variable light domain intermolecularly associate to form an inactive Fv; and wherein the first variable light domain and the first pseudo variable heavy domain intermolecularly associate to form an inactive Fv.
In an additional aspect, Format 3A and Format 3B proteins have sdABD-HSA that have SEQ ID NO: 117 or SEQ ID NO: 121. In a further aspect, Format 3A and Format 3B proteins have sdABD-TTA that binds to a TTA selected from EGFR, EpCAM, Trop2, CA9, FOLR1 and B7H3. The sdABD-TTAs can be selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13; SEQ ID NO:17; SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:57, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73,77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO: 105, SEQ ID NO: 109 and SEQ ID NO:113.
In an additional aspect, the invention provides sdABDs that bind to human Trop2, having a sequence selected from SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89 and SEQ ID NO:93. In a further aspect, the invention provides sdABDs that bind to human B7H3 having a sequence selected from SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53 and SEQ ID NO:57. In an additional aspect, the invention provides sdABDs that bind to human CA9 having a sequence selected from SEQ ID NO:101, SEQ ID NO: 105, SEQ ID NO: 109 and SEQ ID NO:113. In a further aspect the invention provides sdABDs that bind to human EpCAM having a sequence selected from SEQ ID NO:69 and SEQ ID NO:73.
In some aspects, provided herein is a fusion protein comprising, from N- to C-terminal: (a) a first sdABD that binds a tumor target antigen (sdABD-TTA); (b) a first domain linker; (c) a constrained Fv domain comprising:(i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; (ii) a constrained non-cleavable linker (CNCL); and(iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; (d) a second domain linker; (e) a second sdABD-TTA; (f) a cleavable linker (CL); (g) a constrained pseudo Fv domain comprising: (i) a first pseudo light variable domain; (ii) a non-cleavable linker (NCL); and (iii) a first pseudo heavy variable domain; (h) a third domain linker; and (i) a third sdABD that binds to human serum albumin (sdABD-HSA); wherein said first variable heavy domain and said first variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and the first sdABD-TTA and the second sdABD-TTA bind the same TTA selected from the group consisting of B7H3, CA9, EGFR, EpCAM, FOLR1, HER2, LyPD3, and Trop2. In some embodiments, the first and/or second sdABD-TTA can be any sdABD-TTA disclosed herein.
In some aspects, provided herein is a fusion protein comprising, from N- to C-terminal: (a) a first sdABD that binds a tumor target antigen (sdABD-TTA); (b) a first domain linker; (c) a constrained Fv domain comprising:(i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3; (ii) a constrained non-cleavable linker (CNCL); and(iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3; (d) a second domain linker; (e) a second sdABD-TTA; (f) a cleavable linker (CL); (g) a constrained pseudo Fv domain comprising: (i) a first pseudo light variable domain; (ii) a non-cleavable linker (NCL); and (iii) a first pseudo heavy variable domain; (h) a third domain linker; and (i) a third sdABD that binds to human serum albumin (sdABD-HSA); wherein said first variable heavy domain and said first variable light domain are capable of binding human CD3 but the constrained Fv domain does not bind CD3; the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and the first sdABD-TTA bind a TTA selected from the group consisting of B7H3, CA9, EGFR, EpCAM, FOLR1, HER2, LyPD3, and Trop2 and the second sdABD-TTA bind a different TTA selected from the group consisting of B7H3, CA9, EGFR, EpCAM, FOLR1, HER2, LyPD3, and Trop2. In some embodiments, the first and/or second sdABD-TTA can be any sdABD-TTA disclosed herein.
A fusion protein comprising an amino acid sequence consisting of any one selected from the group consisting of SEQ ID NO:288 (Pro565), SEQ ID NO:289 (Pro566), SEQ ID NO:290 (Pro567), SEQ ID NO:292 (Pro727), SEQ ID NO:293 (Pro728), SEQ ID NO:294 (Pro729), SEQ ID NO:295 (Pro730), SEQ ID NO:296 (Pro731), SEQ ID NO:297 (Pro676), SEQ ID NO:298 (Pro677), SEQ ID NO:299 (Pro678), SEQ ID NO:300 (Pro679), SEQ ID NO:301 (Pro808), SEQ ID NO:302 (Pro819), SEQ ID NO:304 (Pro621), SEQ ID NO:305 (Pro622), SEQ ID NO:306 Pro640, SEQ ID NO:307 (Pro641), SEQ ID NO:308 (Pro642), SEQ ID NO:309 (Pro643), SEQ ID NO:310 (Pro744), SEQ ID NO:311 (Pro746), SEQ ID NO:312 (Pro108), SEQ ID NO:313 (Pro109), SEQ ID NO:314 (Pro396,) SEQ ID NO:315 (Pro476), SEQ ID NO:316 (Pro706), SEQ ID NO:317 (Pro709), SEQ ID NO:318 (Pro470), SEQ ID NO:319 (Pro471), SEQ ID NO:320 (Pro551), SEQ ID NO:321 (Pro552), SEQ ID NO:322 (Pro623), SEQ ID NO:323 (Pro624), SEQ ID NO:324 (Pro698), SEQ ID NO:325 (Pro655), SEQ ID NO:326 (Pro656), SEQ ID NO:327 (Pro657), SEQ ID NO:328 (Pro658), SEQ ID NO:329 (Pro516), SEQ ID NO:330 (Pro517), SEQ ID NO:331 (Pro518), SEQ ID NO:332 (Pro519), SEQ ID NO:333 (Pro513), SEQ ID NO:336 (Pro225), SEQ ID NO:338 (Pro817), SEQ ID NO:416 (Pro311), SEQ ID NO:417 (Pro312), SEQ ID NO:418 (Pro313), SEQ ID NO:419 (Pro246), SEQ ID NO:420 (Pro256), SEQ ID NO:421 (Pro420), SEQ ID NO:422 (Pro421), SEQ ID NO:487 (Pro751), SEQ ID NO:488 (Pro752), SEQ ID NO:489 (Pro824), and SEQ ID NO:490 (Pro826) SEQ ID NO:522 (Pro601), SEQ ID NO:523 (Pro602), SEQ ID NO:524 (V3), SEQ ID NO:525 (V4), SEQ ID NO:526 (Pro664), SEQ ID NO:527 (Pro665), SEQ ID NO:528 (Pro667), SEQ ID NO:529 (Pro694), SEQ ID NO:530 (Pro695), and SEQ ID NO:531 (Pro565).
In a further aspect, the invention provides nucleic acid compositions comprising first nucleic acids that encode the first protein members of the prodrug pair and second nucleic acids that encode the second protein members of the pairs, and expression vectors and host cells containing the nucleic acids.
Each protein (e.g. single proteins for Formats 1, 2 and 4) or pairs of constructs (Format 3) were expressed from a separate expression vector (pcdna3.4 derivative). Equal amounts of plasmid DNA that encoded the pair of hemi-cobra or single chain constructs were mixed and transfected to Expi293 cells following the manufacture’s transfection protocol. Conditioned media was harvested 5 days post transfection by centrifugation (6000 rpm x 25′) and filtration (0.2 uM filter). Protein expression was confirmed by SDS-PAGE. Constructs were purified and the final buffer composition was: 25 mM Citrate, 75 mM Arginine, 75 mM NaCl, 4% Sucrose, pH 7. The final preparations were stored at -80° C.
Recombinant human (rh) MMP9 was activated according to the following protocol. Recombinant human MMP-9 (R&D # 911-MP-010) is at 0.44 mg/ml (4.7 uM). p-aminophenylmercuric acetate (APMA) (Sigma) is prepared at the stock concentration of 100 mM in DMSO. Assay buffer is 50 mM Tris pH 7.5, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35.
The concentration of the activated rhMMP9 is ~ 100 nM.
To cleave the constructs, 100 ul of the protein sample at 1 mg/ml concentration (10.5 uM) in the formulation buffer (25 mM Citric acid, 75 mM L-arginine, 75 mM NaCl, 4% sucrose) was supplied with CaCl2 up to 10 mM. Activated rhMMP9 was added to the concentration 20-35 nM. The sample was incubated at room temperature overnight (16-20 hrs). The completeness of cleavage was verified using SDS PAGE (10-20% TG, TG running buffer, 200 v, 1 hr). Samples were typically 98% cleaved.
Firefly Luciferase transduced HT-29 cells were grown to approximately 80% confluency and detached with Versene (0.48 mM EDTA in PBS - Ca - Mg). Cells were centrifuged and resuspended in TDCC media (5% Heat Inactivated FBS in RPMI 1640 with HEPES, GlutaMax, Sodium Pyruvate, Non-essential amino acids, and β-mercaptoethanol). Purified human Pan-T cells were thawed, centrifuged and resuspended in TDCC media.
A coculture of HT-29_Luc cells and T cells was added to 384-well cell culture plates. Serially diluted COBRAs were then added to the coculture and incubated at 37° C. for 48 hours. Finally, an equal volume of SteadyGlo luciferase assay reagent was added to the plates and incubated for 20 minutes. The plates were read on the Perkin Elmer Envision with an exposure time of 0.1 s/well. Total luminescence was recorded and data were analyzed on GraphPad Prism 7 or Version 8.3.1 (depending on timing).
These protocols were used in many of the experiments of the figures.
Tumor cells were implanted subcutaneous (SC) in the right flank of NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (The Jackson Laboratory, Cat. No. 005557) and allowed to grow until an established tumor with a mean volume of around 200 mm3 was reached. In parallel human T cells were cultured in T cell media (X-VIVO 15 [Lonza, Cat.No. 04-418Q], 5% Human Serum, 1% Penicillin/Streptomycin, 0.01 mM 2-Mercaptoethanol) in a G-Rex100M gas permeable flask (Wilson Wolf Cat. No. 81100S) with MACSiBeads from the T Cell Activation/Expansion Kit (Miltenyi Cat. No. 130-091-441) for around 10 days and supplemented with recombinant human IL-2 protein. Tumor growth in mice and human T cell activation/expansion were coordinated so that on Day 0 of the study mice were randomized into groups (N=6) based on tumor size; each were then injected intravenous (IV) with 2.5×106 cultured human T cells and administered the first dose of the COBRA or control molecules. Mice were dosed every 3 days for 7 doses (Days 0, 3, 6, 9, 12, 15 and 18) and then followed for an additional 2-3 weeks until tumors reached >2000 mm3 in volume or the study was terminated. Tumor volumes were measured every 3 days.
NSG-β2M-/- mice (Jackson) were engrafted with i.v. with human PBMC; 3d post engraftment, mice were implanted with tumor cell lines subcutaneously. Once tumor growth was established, mice were randomized based on tumor volume, and test articles were dosed i.v. as indicated. Tumor volume was assessed by caliper measurement. Plasma was collected 4h post-dose to assess cytokine levels (MesoScale Discovery) and liver enzyme elevations.
Note that the key difference between the two protocols is that human T cells are injected at the same time as the first COBRA dose, while in Protocol 2 human PBMC are put in at the same time as the tumor cells and the COBRA injections start about 10 days later.
5 × 106 LoVo cells or 5 × 106 HT29 cells were implanted subcutaneous in the right flank of NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (The Jackson Laboratory, Cat. No. 005557) and allowed to grow until tumors were established. In parallel human T cells were cultured in T cell media (X-VIVO 15 [Lonza, Cat.No. 04-418Q], 5% Human Serum, 1% Penicillin/Streptomycin, 0.01 mM 2-Mercaptoethanol) in a G-Rex100M gas permeable flask (Wilson Wolf Cat. No. 81100S) with MACSiBeads from the T Cell Activation/Expansion Kit (Miltenyi Cat. No. 130-091-441) for 10 days and supplemented with recombinant human IL-2 protein. Tumor growth in mice and human T cell activation/expansion were coordinated so that on Day 0 of the study mice were randomized into groups (N=6) based on tumor size; each were then injected intravenous (IV) with 2.5×106 cultured human T cells and administered the first dose of the COBRA or control molecules. Mice were dosed every 3 days for 7 doses (Days 0, 3, 6, 9, 12, 15 and 18) and then followed until tumors reach >2000 mm3 in volume or the study was terminated. Groups received 0.2 mg/kg (mpk) of the anti-EGFR x CD3 positive control Pro51 bispecific antibody (bsAb), 0.5 mpk of the negative control anti-hen egg lysozyme (HEL) x CD3 bsAb Pro98, 0.5 mpk each of the MMP9 cleavable linker containing anti-EGFR hemi-COBRA pair Pro77 and Pro53, or 0.5 mpk each of the non-cleavable(NCL) linker containing anti-EGFR hemi-COBRA pair Pro74 and Pro72. Tumor volumes were measured every 3 days.
5 × 106 LoVo cells or 5 × 106 HT29 cells were implanted subcutaneous in the right flank of NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (The Jackson Laboratory, Cat. No. 005557) and allowed to grow until tumors were established. In parallel human T cells are cultured in T cell media (X-VIVO 15 [Lonza, Cat.No. 04-418Q], 5% Human Serum, 1% Penicillin/Streptomycin, 0.01 mM 2-Mercaptoethanol) in a G-Rex100M gas permeable flask (Wilson Wolf Cat. No. 81100S) with MACSiBeads from the T Cell Activation/Expansion Kit (Miltenyi Cat. No. 130-091-441) for 10 days and supplemented with recombinant human IL-2 protein. Tumor growth in mice and human T cell activation/expansion were coordinated so that on Day 0 of the study mice were randomized into groups (N=6) based on tumor size; each were then injected intravenous (IV) with 2.5×106 cultured human T cells and administered the first dose of the COBRA or control molecules. Mice were dosed every 3 days for 7 doses (Days 0, 3, 6, 9, 12, 15 and 18) and then followed until tumors reach >2000 mm3 in volume or the study was terminated. Groups received 0.2 mpk of the anti-EGFR x CD3 positive control Pro51 bispecific antibody (bsAb), 0.5 mpk of the negative control anti-hen egg lysozyme (HEL) x CD3 bsAb Pro98, or 0.5 mpk of the MMP9 cleavable linker containing anti-EGFR COBRA Pro140. Tumor volumes were measured every 3 days.
5 × 106 HT29 cells were implanted subcutaneous in the right flank of NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (The Jackson Laboratory, Cat. No. 005557) and allowed to grow until tumors were established. In parallel human T cells are cultured in T cell media (X-VIVO 15 [Lonza, Cat.No. 04-418Q], 5% Human Serum, 1% Penicillin/Streptomycin, 0.01 mM 2-Mercaptoethanol) in a G-Rex100M gas permeable flask (Wilson Wolf Cat. No. 81100S) with MACSiBeads from the T Cell Activation/Expansion Kit (Miltenyi Cat. No. 130-091-441) for 10 days and supplemented with recombinant human IL-2 protein. Tumor growth in mice and human T cell activation/expansion were coordinated so that on Day 0 of the study mice were randomized into groups (N=6) based on tumor size; each were then injected intravenous (IV) with 2.5×106 cultured human T cells and administered the first dose of the COBRA or control molecules. Mice were dosed every 3 days for 7 doses (Days 0, 3, 6, 9, 12, 15 and 18) and then followed until tumors reach >2000 mm3 in volume or the study was terminated. Groups received 0.1 mg/kg (mpk) of the anti-EGFR x CD3 positive control Pro51 bispecific antibody (bsAb), 0.3 mpk of the of the non-cleavable (NCL) control linker containing anti-EGFR COBRA Pro214, 0.1 or 0.3 mpk of the MMP9 cleavable linker containing anti-EGFR COBRA Pro140, or 0.1 or 0.3 mpk of the MMP9 cleavable linker containing anti-EGFR COBRA Pro186. Tumor volumes were measured every 3 days.
The results are shown below.
These results show both that the humanization of the EGFR binding domains was successful, and that there is strong avidity to the target EGFR when two binding sites are on the molecule.
The results are shown below.
These results show both that the humanization of the EpCAM binding domains was successful.
Despite clinical success with bispecific antibodies (bsAbs) targeting hematological malignancies (e.g. blinatumomab, a CD19xCD3 bsAb), efficacy in solid tumor indications remains a significant challenge. Because T cell redirecting bsAbs are so potent, even very low levels of cell surface target antigen expression on normal tissues may quickly become a safety liability and severely restrict the dose levels that can be achieved in patients. This limits the likelihood of reaching efficacious concentrations and reduces the therapeutic potential of these highly active molecules. Additionally, identifying “clean” target antigens that are uniquely expressed on the tumor and not on normal tissues has been very difficult at best.
To overcome these challenges, we have developed a novel recombinant bsAb platform called COBRA™ (Conditional Bispecific Redirected Activation). COBRAs are engineered to enable targeting of more widely expressed and validated tumor cell surface antigens by focusing T cell engagement within the tumor microenvironment. COBRA molecules are designed to bind to target antigen, which may be expressed on both tumor and normal cells, yet not engage T cells unless exposed to a proteolytic microenvironment, which is common in tumors but not in normal healthy tissues. Once bound to the tumor target antigen, protease-dependent linker cleavage allows COBRAs to convert an inactive anti-CD3 scFv to an active anti-CD3 scFv binding domain. Upon conversion, COBRAs are then able to simultaneously co-engage T cells and target antigen, resulting in a potent cytolytic T cell response against the tumor cells. In addition, COBRAs are designed with a half-life extension moiety that is removed from the active molecule upon proteolytic cleavage. This allows for a sustained presence in the circulation of the inactive COBRA prior to tumor target binding, and more rapid clearance of unbound active COBRA molecules, thereby decreasing the potential for cytotoxic activity in normal tissues.
Here we have revealed the novel design of the COBRA molecule and demonstrate its ability to engage CD3 and Epidermal Growth Factor Receptor (EGFR) to elicit potent cytotoxic activity in T cell culture and in human T cell implanted tumor-bearing mice. We have reported low-to-sub-picomolar T cell activation and cytotoxicity in vitro, and COBRA linker cleavage dependent T cell mediated regression of established solid tumor xenografts in NSG mice in vivo.
Conclusions: We have designed a multivalent sdAb-diabody fusion which converts into a highly potent bispecific redirected T-cell therapeutic upon proteolytic action. In vitro assay demonstrated that protease dependent linker cleavage increased potency of T cell-mediated killing by 200-fold, thus yielding a therapeutic with sub-picomolar potency. Administration of PRO186 (Pro186) in mice with established xenografts resulted in protease cleavage dependent T cell-mediated tumor regressions in multiple tumor models. PRO186 displayed (1) extended half-life in vivo upon administration and (2) rapid clearance post proteolytic activation, thereby demonstrating PRO186 to be a therapeutic with improved safety profile over conventional T-cell redirected bispecifics.
Human HER2-Raji cells, cynomolgus monkey (cyno) HER2-Raji cells, SKOV3 cells (low expressing HER2 cells), Raji-paternal cells, HT29 cells (high expressing HER2 cells) were tested with various fusion proteins: Pro1123 NCL, Pro1117 MMP9, Pro 1117 MMP9cl, Pro1060 Pro51, and Pro1069 AD (
aHER2 fusion proteins in a Pro51 format and containing one aHER2 sdABD such as either the VIB1139 HER2 sdABD, the VIB1156 HER2 sdABD, the VIB1159 HER2 sdABD or the VIB1162 HER2 sdABD demonstrated good activity against human and cross-reactivity with cynomolgus in TDCC experiments (
The epitope binning experiments of various HER2 sdAbs were performed as understood by those skilled in the art. Competing antibodies at 100 nM were tested with saturating antibodies at 333 nM. The tested competing antibodies were: Pro1118, Pro1111, trastuzumab, and pertuzumab. The saturating tested antibodies were: the VIB1121 HER2 sdABD, the VIB1139 HER2 sdABD, the VIB1058 HER2 sdABD, the VIB1097 HER2 sdABD, trastuzumab, the VIB1156 HER2 sdABD, the VIB1160 HER2 sdABD, the VIB1159 HER2 sdABD, and the VIB1162 HER2 sdABD (
The epitope binning experiments of various HER2 sdAbs were performed as recognized by those skilled in the art. Competing antibodies at 100 nM were tested with saturating antibodies at 333 nM. The tested antibodies were: Pro1118, Pro1111, trastuzumab, and pertuzumab. “B” indicates binding of competing Ab and “NB” indicates no binding of competing Ab (
The amino acids locations and sequences from the epitope mapping analysis of HER2 sdAb h1156 (Pro1061) and HER2 sdAb h1162 (Pro1064) were identified using HDX (hydrogen-deuterium exchange), performed as recognized by those skilled in the art (
The binding affinities of HER2 sdAbs in Pro51 format were determined. Various sdAb and fusion proteins combinations were assessed with targets from human, cynomolgus monkey and mouse. The combinations were the following: 1055 and Pro1036; 1058 and Pro1037; 1059 and Pro1038; 1091 and Pro1039; 1092 and Pro1040; 1097 and Pro1041; 1121 and Pro1042; 1139 and Pro1043; 1156 and Pro1044; 1159 and Pro1045; 1160 and Pro1046; 1162 and Pro1047; h1058 and Pro1056; h1092 and Pro1057; h1097 and Pro1058; h1121 and Pro1059; h1139 and Pro1060; h1156 and Pro1061; h1159 and Pro1062; h1160 and Pro1063; and h1162 and Pro1064 (
Human CA9-Raji cells, cyno CA9-Raji cells, and HT29-parental cells were tested with various fusion proteins: Pro514 NCL, Pro518 MMP9, Pro518 MMP9cl, Pro511 Pro51, and Pro521 AD (
Human CA9-Raji cells, cyno CA9-Raji cells, and HT29-parental cells were tested with various fusion proteins: Pro515 NCL, Pro519 MMP9, Pro519 MMP9cl, and Pro512 Pro51. Monospecific COBRAs targeting CA9 such as those comprising aCA9 sdABDs (aCA9 h445) were able to kill human or cyno CA9 expressing tumor cell lines conditionally (
Human CA9-Raji cells, cyno CA9-Raji cells, and HT29-parental cells were tested with various fusion proteins: Pro1095 NCL, Pro516 MMP9, Pro516 MMP9cl, and Pro509 Pro51. Monospecific COBRAs targeting CA9 such as those comprising aCA9 sdABDs (aCA9 h456) were able to kill human or cyno CA9 expressing tumor cell lines conditionally (
Human CA9-Raji cells, cyno CA9-Raji cells, and HT29-parental cells were tested with various fusion proteins: Pro513 NCL, Pro517 MMP9, Pro517 MMP9cl, Pro520 AD and Pro510 Pro51. Monospecific COBRAs targeting CA9 such as those comprising aCA9 sdABDs (aCA9 h4) were able to kill human or cyno CA9 expressing tumor cell lines conditionally (
CA9 monospecific COBRAs of Format 2 and comprising an MMP9 cleavage linker (CA9/MMP9 COBRA) were able to regress established tumor xenografts.
Raji-parental cells (
Pro624 comprises from N- to C-terminal: (sdABD-EGFR)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-EpCAM)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). Pro698 comprises from N- to C-terminal: (sdABD-EpCAM)-domain linker-aVH-CNCL-aVL-domain linker-(sdABD-EGFR)-CL-iVL-CNCL-iVH-domain linker-(sdABD-HSA). EGFR/EpCAM heteroCOBRAs were also able to induce TDCC on HT29 cells expressing one or both antigens.
EGFR/EpCAM heteroCOBRAs comprising an aEGFR sdABD (aEGFR hD12) and an aEpCAM sdABD (aEpCAM h644) were tested with Pro623 MMP9, Pro623 cleaved, Pro625 NCL (
EGFR/EpCAM heteroCOBRAs comprising an aEGFR sdABD (aEGFR hD12) and an aEpCAM sdABD (aEpCAM h665) were tested with Pro698 MMP9, Pro698 cleaved, 699 NCL (
Raji-EGFR cells (
The affinities of EGFR/FOLR1 HeteroCOBRA vs Pro51 format molecules were assessed and are listed in
Raji-Trop2 cells (
Raji-Trop2 cells (
Raji-Trop2 cells (
Raji-Trop2 cells (
B7H3/EpCAM heteroCOBRAs were shown to induce TDCC on cells expressing one or both antigens. Raji-parental cells (
Experiments were performed in CRISPR knockout lines: HT29 cells (
H292 cells were tested with Pro295 NCL (B7H3 hF7), Pro225 MMP9 (B7H3 hF7)and Pro225 MMP9cl (B7H3 hF7) (
HT29 cells (
T cell activation in the presence of HT29 cells was determined using standard Jurkat luciferase assays known to those skilled in the art. The HT29 cells were tested with monospecific COBRAs: Pro225 (B7H3/B7H3) and Pro566(EpCAM/EpCAM) and with heteroCOBRAs: Pro656 (B7H3/EpCAM) and Pro658 (EpCAM/B7H3) (
The activity of heteroCOBRAs in the Jurkat activation assay were shown to be less sensitive to inhibition by soluble antigen than with monospecific COBRAs on HT29 cells. The cells were assayed with soluble EpCAM, soluble B7H3-4Ig and with no antigen (control) together with monospecific COBRAs: Pro225 (B7H3/B7H3) (
Antigens huB7H3-4Ig, huEpCAM and huB7H3-4Ig with huEpCAM were assayed with heteroCOBRAs: Pro656 B7H3/EpCAM and Pro658 EpCAM/B7H3 and
The pharmacokinetics of B7H3/EpCAM heteroCOBRAs (
In vivo activity of the heteroCOBRAs were determined in the HT29 cell line xenograft model in mice. HeteroCOBRAs were administered at the following dosages: Pro660 NCL (B7H3/EpCAM; 0.3 mg/kg), Pro656 MMP9 (B7H3/EpCAM; 0.01 mg/kg), Pro656 MMP9 (B7H3/EpCAM; 0.03 mg/kg) and Pro656 MMP9 (B7H3/EpCAM; 0.1 mg/kg). The B7H3/EpCAM heteroCOBRAs were active in mice (
Additional heteroCOBRAs were tested in the HT29 cell line xenograft model and administered at the following dosages: Pro662 NCL (EpCAM/B7H3; 0.1 mg/kg) and Pro658 MMP9 (EpCAM/B7H3; 0.1 mg/kg). The B7H3/EpCAM heteroCOBRAs were active in mice (
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Pat. Application No. 63/313,213, filed Feb. 23, 2022, entitled “CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS,” which is hereby incorporated by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 63313213 | Feb 2022 | US |
